{"docstore/metadata": {"0e7f7ed6-dd2c-492e-b25a-0a216cd706af": {"doc_hash": "1c2db4845a5fdcf256b0bb2ce47e928defb762f75264bc56d36b23f0fa745374"}, "8b0e3e89-0d16-4579-a5ab-ae7ac473f101": {"doc_hash": "aaba245787cdaf9c975661938f3fe5cbd33efde49fbfbe3160cceff65d1283d5"}, "40c6500b-1254-4267-ab2c-1d6ac179494f": {"doc_hash": "928d19242c30a0b9e5a90e05201d988a4939e0ed13241a1dfd33c34de519c012"}, "6eb198ce-f6c2-49cd-a09a-bb8180659209": {"doc_hash": "eebb34b6f9ae9f2d54d4eb2ec954133784b9c11ea5fd778b47f1e825717e4c8e"}, "3a2f5240-d16f-4c31-a107-eccccaf90dde": {"doc_hash": "23e0f3653dd32d5c537ffade681b0c50d66b7e4e891bac5a2e1683d5c0eed417"}, "2e6f775f-d3ec-40bf-a1f5-d6ea3f2a3303": {"doc_hash": "9f28241e1b342f9e92f1fbcc2374d648bf44364ab36225e4dd8ea62afc24aa74"}, "b6e9355c-9a05-425e-b5cb-5fbcaea7a89b": {"doc_hash": "894ddfdc394dd9f3e1d842c1932e3d887257ef3c3cb689f583d62cbc592b9dc2"}, "141d1fb5-dacf-45eb-9d98-940e27f3aaa2": {"doc_hash": "0ab2d5dff3fe51c7e2d39e93b89eb9eb38579b79de9a9b6a556d40d7bab407d5"}, "e4a1b712-c9d9-4f65-b582-d462feccb448": {"doc_hash": "d1dfc47faad8fcc85f870ae2dc075a318a39b5a715b1d8b63afeaba71e4ab402"}, "861446fe-d825-47fa-956c-f74f4d730322": {"doc_hash": "a78528704d7739ea300113e0519bf777791343970a89cb3b426e17b992e22974"}, "05c1bcb4-a4be-4e7d-aa96-ed238f3fe9ae": {"doc_hash": "3e4a7a4f26087e13db828cd2841ece4c6019b89594243dfc3c95212d23282fef"}, "48ea414d-c6af-4562-b882-803a155b761a": {"doc_hash": "43c452da790dd26bcb7394d0ca571644ce4a6845de6e99ef31c56cd4175e23ce"}, "1efae18d-ae1d-4f42-9ecc-3630b6e5f147": {"doc_hash": "8a4cef343626413a6edf3ed0fcfb19d5cba7ed25407be8ba0af38c3e9c85ffe1"}, "3304ff88-a04c-47b3-ad7b-a7b70be04be6": {"doc_hash": "e433d195969c85f44c6c9428073fd91349f3ec8d4d1449ab253c17b57e83070a"}, "48a4b216-fe1c-41f2-bb91-d2167685a31a": {"doc_hash": "f693089cf88b8f9ccc2239997309852009c2bf726f625dd47ff9a98f21de1a86"}, "6f72aac8-e4ad-4875-aa99-4621e500638d": {"doc_hash": "07890e70b16e1c165609ae77d9957acfc19066b1a692f09572bd05de8f4816b0"}, "ce49db4c-c279-4a36-bb67-1a4e482f7d47": {"doc_hash": "719c480ad2b232b2f6070261800bc88c696b9041b411e05ea6bd967a38d03ab0"}, "918cd242-658d-4dce-b20a-1cdbec0ff4ce": {"doc_hash": "3a89c26639453a8d989acc1047caecb61f5cec5567bb67803ccf157f8c75d692"}, "fecfc4d3-7869-4674-bda1-aaa1972715fc": {"doc_hash": "bc4bfb773df7d4a2a4d21ef77bb83fe4ba5fdbee5fa93e546b4bccb5122e47fe"}, "0ce131af-0418-4b0c-b581-18dea087bd33": {"doc_hash": "8572139bd7c2a49237cc7503a47a9dabc9dc6de3bc4dc9d74e45a2d4c561dd4b"}, "900de44e-7639-49df-add3-000b06fcc600": {"doc_hash": "09929853fda6b12ef3f35873d2a86b5211e2f76938b6da24577ddbb4e94e0bb0"}, "1f3ca2db-b749-46c7-89ac-009bba6a755b": {"doc_hash": "7b59d2f229e5bcb890a6530980661ed8d41c4add66fe9e4bc8eba177bd633b5d"}, "0fe0f9ae-393c-4c34-a3c6-7c0b3a8f3111": {"doc_hash": "d1ae213263ca07d39f9306b5477eaaa6bf5a7f05715c3302a6e8a07481dcc840"}, "38d6a9cb-503d-423e-adc8-a63cf7f5c5a0": {"doc_hash": "fe137e3535831859af6f6ba22fc88c01583f1978788ba758296cd0d7f74f2ef2"}, "13c6c55d-232f-4ac9-bb04-ff25df9de458": {"doc_hash": "59aef84a462759f69d69512f7ba7545f805eec27938f313f701cfed911f7b73e"}, "e260dda8-0825-4524-b466-877aaa8af6d9": {"doc_hash": "2dc7575ea29ba0c6180f04d11c7bbc876ea7111267759b23fe1842631da2ccf7"}, "bc792108-53c1-490c-9e75-1b3e066026f7": {"doc_hash": "ee098a7cbd60a4985af9bcb2bb9cfd00da5b016be3e89702dcacdb420ee0b5b3"}, "07818704-808e-46b9-a7b0-9762a45a734c": {"doc_hash": "ef26b70ca12fe89a371970d85b8fe6b0644ec3ce6afee038aba2e6d0689057e9"}, "dfa3f582-94c8-4371-98f1-ef65ac685138": {"doc_hash": "c4ed2a3d57a188190736143818bda3e0d4fde36e3dddc1f06d9dc619017fe91c"}, "8b5e46e4-6d82-4591-b0d2-02a4cddb69eb": {"doc_hash": "36355c862b30f6eb9c1adcb93596204186eb9d5bd013d2d7508f9ce37073d197"}, "da290cdc-d2ce-468f-a622-6d9c9bb2abd6": {"doc_hash": "836a6dfe3eeab68addb661b5a6f12de911bd34a204b5a8f38d2525837558788b"}, "e9792f8b-ef6f-4ba1-8f5f-75a59b3f5cd5": {"doc_hash": "ee2f0c9430399fefaab4a5bd7349ac845d74c9e6e24d44bfe5523137b2acdd20"}, "e97110f5-6142-4cf3-992b-a5860d149be2": {"doc_hash": "7d00442df88ee2aca187e57cf4350e167d3124ec96db9ab914ae965fb8e3c5e5"}, "97115d27-cb40-40f6-b8d4-b940d1fbb302": {"doc_hash": "66b519364278ee3f698d8f3c55407d2e3b0215530d0a921bb662e37d4bee974f"}, "2d58961a-0571-4525-936d-6b48a93435ea": {"doc_hash": "2ba28d0511a44c750c98a14682969587a3d3a1cd5cfc989805675ea315541e8f"}, "4a4cf3bc-1f30-41d6-ad0e-3c4d2766941e": {"doc_hash": "e5bb19e365ca80af13dae632a28708f74d3e06fee8c1a8f53fb59ba819676cb2"}, "b5952c43-41a2-47d7-b2ca-c1737bdaeb93": {"doc_hash": "be58d46cba50e11e31a5d165f498738dcc2e38c65d0d845256fe08b9b0e118e2"}, "bea62208-6772-4058-9f03-3da59893bc45": {"doc_hash": "29b2a5a37d0399ec95940dc4e918b16c2c60f3cf17d11baa3da3bc2a1f85d148"}, "240bcf4f-e2d4-493a-b8cc-2d31d6dfa3f3": {"doc_hash": "dea86043d41689fa98c53b785aa97fbc2e3582b89ae694882f182dfdb5a1e85c"}, "a12f41e7-5b11-4a47-a46b-bda98ecc4fb7": {"doc_hash": "f14d3809b6013c0bc2a88a905b5626bc9cf71dfd26ff38f3915dfa8330afe0d1"}, "f17fec79-7d92-4e31-b263-4b546d50c619": {"doc_hash": "fb498e0979881400eb62650cd64246654f4f1b0e198e70c626d2d5bf4346e796"}, "2a55a4fe-af83-46b2-8140-86f11a7707ff": {"doc_hash": "0e34e9926235c4437eb3e02daf5f6fac9800c5303ed1966e6fd8a4af73815a32"}, "2a2fb3b0-7524-4546-b2bb-3f5ea854c3ba": {"doc_hash": "6b0712c9ebb4a6ad0fd3c35b07b39aa5820e70215dc06ff75481cfa63f6ced43"}, "7cbdc3c1-5fea-482b-9014-7b4436534817": {"doc_hash": "6b19d31ba2ec463f0fda05ee27f9d70c93affdeb1d73334430cb380c509b4604"}, "b365dfd4-fc81-4eba-b7c5-aceec8307475": {"doc_hash": "cac14335aa648e0897cde66713bbc2a9de06cf34b3c506f6f454dd4b155435a9"}, "dcc545cf-a6f2-4c1d-a78c-6d5d457731ef": {"doc_hash": "8f5adfd53421c380b88c2d23c3320bf1c3dbf1f63f6689136e4b4656d4f225e0"}, "dfe261a9-4249-4fb1-a2cc-c4391a005447": {"doc_hash": "cc8057477334d6ca1b9a01ca1b3e32bf09210fd263f6a25c48dcc09030851477"}, "f37f44cf-6a50-4f0f-9dfc-5c4d61ed6e7b": {"doc_hash": "b2051f6e53e9cd9a1aae788e45154bc318d06e3affe3f3d7110152880f7dc346"}, "1368e1c6-16ee-4795-a25b-a95225298012": {"doc_hash": "709270c290d849923b2b4c47dda6fe7bda50bb5ce689a85a3390bc746e829a0b"}, "8e4ab208-ccaf-4c0d-924c-28ed7f9c6dd9": {"doc_hash": "10fd48223f7c326c496e5b8825b892eeddf46317417eba75f27e3b6a1aff1bf8"}, "322ce154-6a70-4d4e-bc3e-2db338c6b258": {"doc_hash": "1c181970c642c636a126adb9f49d9b36e9c64e6f6084fd0dd2a456a997ae7da1"}, "ffeedfa5-0485-4713-a8b8-be5352df805d": {"doc_hash": "7fd93a2bc0cb6329be0dc74392c76d59bdd746264f93c47d78cdb601704b359b"}, "bee0412b-b3c4-47fd-b240-21b5feaeb4ac": {"doc_hash": "15c19d82804b06ed6e9d4eb1b7ded7f18df75a11ec88bc4eeeadbacf80810870"}, "0153d763-c827-49a8-9d7f-4bf6ba531047": {"doc_hash": "e42e908bda4f4e4f23ae17a96c3866d51beef610466e37a9faee7956b99d2a18"}, "35f8a887-8d06-4f34-b818-b180e9405fa4": {"doc_hash": "da256c2d6f630767575cdbb75e1a1c0674d5801743500294d71a0898d524c593", "ref_doc_id": "0e7f7ed6-dd2c-492e-b25a-0a216cd706af"}, "7cd4eb54-733e-4431-9343-a42c8831424c": {"doc_hash": "cc498fc9f3fbebddfdb4665b943e9596ad0ae604c3eb5088c77329888ea27d96", "ref_doc_id": "8b0e3e89-0d16-4579-a5ab-ae7ac473f101"}, "b9b8e4ce-cd7b-42fd-8b8a-fac4d9dc9ef2": {"doc_hash": "cb2d7c5a798f72bca9ad04cf2bd3a0ea354d2d785ec71d68193ff614a6110049", "ref_doc_id": "40c6500b-1254-4267-ab2c-1d6ac179494f"}, "77440028-4e6b-4d39-a0d1-afe59196e5ba": {"doc_hash": "b977b437f7c46c93423536b24c08b89c15305dc4b15562e45f705f12afb3de5f", "ref_doc_id": "6eb198ce-f6c2-49cd-a09a-bb8180659209"}, "2369fd3e-aa24-4778-a0c3-04597c5057fd": {"doc_hash": "4c0361057778d7b74f0e55b398f93d1c96f8277ba59eb2591745e47658c2f51f", "ref_doc_id": "3a2f5240-d16f-4c31-a107-eccccaf90dde"}, "ea7eb0b3-a83e-4ed9-ae7c-c070ed8e8d51": {"doc_hash": "557bfef26bcef0a116f18fa55a747e12118335abbeddf8b4eff47e5a48d2eb1a", "ref_doc_id": "2e6f775f-d3ec-40bf-a1f5-d6ea3f2a3303"}, "4257d4e0-a6ec-45db-aa5c-27aefd1f4f64": {"doc_hash": "877544e63179623dbdbef9254e2e8248c7c0020cf45228b5459de172e8fa9541", "ref_doc_id": "b6e9355c-9a05-425e-b5cb-5fbcaea7a89b"}, "7b853469-8f28-421e-9583-2a1f27e6e19d": {"doc_hash": "87b38de4687b9900642d2c1dfa0480ab8940a33de5817304397812e9b6002d99", "ref_doc_id": "141d1fb5-dacf-45eb-9d98-940e27f3aaa2"}, "24dc84c8-38b6-486f-a3fb-16846933da08": {"doc_hash": "e89cc959c984b0f6d2b2e3b452bcd4262e86b89ab16a05c53e69cb3a81daed6c", "ref_doc_id": "e4a1b712-c9d9-4f65-b582-d462feccb448"}, "1877f1de-e69d-47c6-b3c6-2d4d601031c8": {"doc_hash": "dd19c10d29a3173be517dfa3bf1a6621a49af4677bfbb99ccdda6588302fefdb", "ref_doc_id": "861446fe-d825-47fa-956c-f74f4d730322"}, "7526ab4e-c6ab-48e3-af87-0fcab7259c11": {"doc_hash": "400d29609158857f8134b9293479ed7f1ffe3662896ee62c94b13e2471c6126d", "ref_doc_id": "05c1bcb4-a4be-4e7d-aa96-ed238f3fe9ae"}, "63718a53-7913-4c23-99c7-8d6db65fc2dc": {"doc_hash": "f4c6f6129598cdf27aa7f686064681256e93ecee811216caddb0f8df90c7cee8", "ref_doc_id": "48ea414d-c6af-4562-b882-803a155b761a"}, "cfd9666c-fe34-4a10-874f-f3df75ecbaa0": {"doc_hash": "2ad3645b32535eca57e8ce50abfe40409d75a3ea73b610e7c19e19462ebe5b75", "ref_doc_id": "1efae18d-ae1d-4f42-9ecc-3630b6e5f147"}, "8fd5be10-ad17-4324-a411-2168e1086ce4": {"doc_hash": "581538a656626213f778c309046afa232c77a6feef7c7978a53879d7b40cf063", "ref_doc_id": "3304ff88-a04c-47b3-ad7b-a7b70be04be6"}, "434d41f4-f4cf-47fa-9958-d75206545a7b": {"doc_hash": "e0361a347bfe58f7830faa6e50f5a7708a5034ecdd05a011dee7d85a9b7a18e7", "ref_doc_id": "48a4b216-fe1c-41f2-bb91-d2167685a31a"}, "7b0393cc-969b-40b2-a692-43405cd84a7c": {"doc_hash": "de9a7a4f439d8c40a232dc3d230d823b62dc64287b3a9cb28d16451a9b31ff31", "ref_doc_id": "6f72aac8-e4ad-4875-aa99-4621e500638d"}, "0b461e9d-ebbc-42b5-9218-35df7c8f8fc1": {"doc_hash": "ce38e47b1da7b542d328462cd3ceded955ef4ba1ffc7bd21072059857805aee1", "ref_doc_id": "ce49db4c-c279-4a36-bb67-1a4e482f7d47"}, "7d3be164-8bbe-4a12-a2c0-757c96a3b200": {"doc_hash": "77a63d3039eb03e0799ce1c3eb1c4b16eaf74c63c4acd8ffc9fb385178c77a32", "ref_doc_id": "918cd242-658d-4dce-b20a-1cdbec0ff4ce"}, "860f2558-712c-40e9-a4c4-e37340f1bcca": {"doc_hash": "4eabe9d9306cf359ecf0adb732cff0793ae24709cabe7e0d0c9af8ddcde6b77c", "ref_doc_id": "fecfc4d3-7869-4674-bda1-aaa1972715fc"}, "db0575d4-4e4f-4e70-8bfb-57ad69ac0b40": {"doc_hash": "983529aa6af424be05a89af8ca7d5a676267a3ea8de5c00b30befd15250123c3", "ref_doc_id": "fecfc4d3-7869-4674-bda1-aaa1972715fc"}, "943941ff-1200-4102-b561-5872cafb0abe": {"doc_hash": "05d25cabcfe440e839f9e50613c6d7cf30f84b9578bb90101604a85dd5d7617b", "ref_doc_id": "0ce131af-0418-4b0c-b581-18dea087bd33"}, "8d997c00-1ade-42b5-afc4-e317bf922e6c": {"doc_hash": "7e8d2144c447117fe13ef5a16f2f28faab19c9899e558cf925c58e497be977d2", "ref_doc_id": "900de44e-7639-49df-add3-000b06fcc600"}, "abadaa34-32ea-43b3-aea3-e4f3a49b7d54": {"doc_hash": "f8617c6dd333e8c5d8901862214a274c2f20268aa638c96dc162ad857ab47b92", "ref_doc_id": "1f3ca2db-b749-46c7-89ac-009bba6a755b"}, "dd5388ff-a97b-4ae6-bab3-d18cdcf3879e": {"doc_hash": "5ce52ae0c689438f99f87466c10f148652113ba8e4a51efc0982284573595cc9", "ref_doc_id": "0fe0f9ae-393c-4c34-a3c6-7c0b3a8f3111"}, "04f45ab3-c799-48b6-ad7d-f030a559f167": {"doc_hash": "0ab3e5c520386cfc5ac98af909768dad00fc8e0f379ae3c1c0762ba43d53bd66", "ref_doc_id": "38d6a9cb-503d-423e-adc8-a63cf7f5c5a0"}, "cd1029ad-3a86-40ad-8447-7cf6b30649a0": {"doc_hash": "33619aed86a08f9641590d67046f21ad0b40143881b4a247ada95aab22da87d7", "ref_doc_id": "13c6c55d-232f-4ac9-bb04-ff25df9de458"}, "7ea7f89a-5aaa-415e-bb18-581e9818d578": {"doc_hash": "8be1b66506733178b481e35592e1c3af0ec56687a9fa0dd23f0a0520abfa3ae9", "ref_doc_id": "e260dda8-0825-4524-b466-877aaa8af6d9"}, "8310758c-9655-4a9e-abde-f311bb289f88": {"doc_hash": "14697df68d3c8de7b5318a19382b1f41383bcae19d03a7c2280165d9e74d2031", "ref_doc_id": "bc792108-53c1-490c-9e75-1b3e066026f7"}, "00179ca1-35c4-4a9d-87c9-91878b48232b": {"doc_hash": "1a83fd2e59fb5da85333ab3ca4ca6beb19d0c463e94e968d2e309e9341f159da", "ref_doc_id": "07818704-808e-46b9-a7b0-9762a45a734c"}, "659a65af-a1bd-40b1-a414-c2cf67a5136b": {"doc_hash": "5729e6a21dd3a48c7c34afd652a75a94927a6240de5045830ef46dfa97c73615", "ref_doc_id": "dfa3f582-94c8-4371-98f1-ef65ac685138"}, "130c24ec-093d-47e6-86b0-aeb7c2599c40": {"doc_hash": "6c67af825b858252e0eb42045be2a8bb77503dd154bc1cd4e4bb671769a44667", "ref_doc_id": "8b5e46e4-6d82-4591-b0d2-02a4cddb69eb"}, "2882bdd5-0512-49fc-a353-7e72b05fe388": {"doc_hash": "1ac6b6e8989da934745e424477c6f3581565b2b8a82c1bbac505c2dd6bf9bf02", "ref_doc_id": "da290cdc-d2ce-468f-a622-6d9c9bb2abd6"}, "fc5221fa-3b37-4928-b7fb-f75e62c1408f": {"doc_hash": "be044602b7caec637a579eaf27aef60334f560b0008279b736d735a9d261a766", "ref_doc_id": "e9792f8b-ef6f-4ba1-8f5f-75a59b3f5cd5"}, "54560577-da4b-4006-94ff-f2ca49994905": {"doc_hash": "bd0114154b9739ce057a931302115a0542edecbf6d7fc607d2b567c6cef5c25e", "ref_doc_id": "e97110f5-6142-4cf3-992b-a5860d149be2"}, "f56b64a7-f527-4296-b880-98756d6531cb": {"doc_hash": "689a104405bca077e35263235f025ccb136746651796a68973dd63041eb481d8", "ref_doc_id": "97115d27-cb40-40f6-b8d4-b940d1fbb302"}, "ce474a38-adf2-48ed-93bc-431d8249093d": {"doc_hash": "de7e9d367c93819e9179569ac53506c8190b2c2797cb423b063651560b5a5542", "ref_doc_id": "2d58961a-0571-4525-936d-6b48a93435ea"}, "2996b545-c7c8-4dca-afc7-26f32ef4b779": {"doc_hash": "6d2961fd6703fca83e828b3ef45fd65d0bf1c42961052f359cc69b73d375ffaa", "ref_doc_id": "2d58961a-0571-4525-936d-6b48a93435ea"}, "c2b62843-6dcb-4268-a8c7-9bcc036e1fd8": {"doc_hash": "790c0ded9e1edbea729f54a44d5e27c9b8e98d4d1b262b1486e8ab56ade66712", "ref_doc_id": "2d58961a-0571-4525-936d-6b48a93435ea"}, "856106da-ca0b-4ffc-a3ed-994c6b11616b": {"doc_hash": "da8b966590a8b2c8001ed311613a63149541cf38ff228fa25c2cbcd93afa830d", "ref_doc_id": "4a4cf3bc-1f30-41d6-ad0e-3c4d2766941e"}, "323820fb-677b-47f9-b987-dba191801d42": {"doc_hash": "6cfcbe30e1caf3775e8084125c805a91534f1afedd9a5377867f0d3ff3a4946a", "ref_doc_id": "b5952c43-41a2-47d7-b2ca-c1737bdaeb93"}, "8b95b6c8-8e95-426d-a86a-d0b5388153b7": {"doc_hash": "98135cecea67e495963d1536e16d48fcc6264248238dea51fd788c0f09358718", "ref_doc_id": "b5952c43-41a2-47d7-b2ca-c1737bdaeb93"}, "cbf83524-0535-4353-90b3-a07e2615dd44": {"doc_hash": "d3ef4131eb0c535075d33e86ea7eda3448c45ff1ae37b8181a9a31f92f8e4dcf", "ref_doc_id": "bea62208-6772-4058-9f03-3da59893bc45"}, "1164f7a9-b54f-43bb-9e38-7806f52e2586": {"doc_hash": "524c430b2e0effc05888c4297ba378c7b198f1a03617634d2803acb2bfa962db", "ref_doc_id": "240bcf4f-e2d4-493a-b8cc-2d31d6dfa3f3"}, "a8575b05-e9a3-4a71-a478-44c2d07edf0b": {"doc_hash": "1e5b8498dbf65ca0588f7d0036015c233c93f60f5e089ba24c2f4ed446d27529", "ref_doc_id": "a12f41e7-5b11-4a47-a46b-bda98ecc4fb7"}, "835c77f8-1e01-4680-a939-1cc3b682440e": {"doc_hash": "8700b6bcfb7d03cbc1fc33172689d49b27a117269e39271852c743c5d7808bae", "ref_doc_id": "f17fec79-7d92-4e31-b263-4b546d50c619"}, "495c3018-429f-4539-ba44-47ae5301449e": {"doc_hash": "3b52205054178cd9520eec1e3c774bbf0f62746c8920f0fde12fc916f97748c9", "ref_doc_id": "2a55a4fe-af83-46b2-8140-86f11a7707ff"}, "24a0081b-bb10-439c-93e5-d8d9c7999762": {"doc_hash": "8135bf44dcc165fcf5d1f2c947657240576dadd35d613703abbbba154b26ef60", "ref_doc_id": "2a2fb3b0-7524-4546-b2bb-3f5ea854c3ba"}, "dc3f7922-8748-439d-bd7b-dc35f44a8247": {"doc_hash": "079609ff61c710a2387e454a763eb290731fbc52f6d779b7fb5351ac880c80a7", "ref_doc_id": "7cbdc3c1-5fea-482b-9014-7b4436534817"}, "ef140abc-84bb-45c5-9869-226fcbe92386": {"doc_hash": "ee7f445e77fbf1cd080ba1bd2e5f57e6b206ed42c3806901b45761b24b5c8344", "ref_doc_id": "b365dfd4-fc81-4eba-b7c5-aceec8307475"}, "696d2370-e7ed-4b0f-ba9c-5b3ca5aaa83f": {"doc_hash": "4c571df40f69b7517e9c6413bf3b0fb44e11f516f6183d35b1a6b4ec4d2ea9f2", "ref_doc_id": "dcc545cf-a6f2-4c1d-a78c-6d5d457731ef"}, "ba81e23b-40c2-4fe4-b4b2-71f60798df24": {"doc_hash": "77cfb9c99c061b01aeca71e9ea9d7e8f808bd0ac8085d9d193eea76c81d15099", "ref_doc_id": "dfe261a9-4249-4fb1-a2cc-c4391a005447"}, "762a0144-680d-473e-8f71-d5fc8125edaf": {"doc_hash": "04cd727a770ab9bfbd8e88ed39833ee37bd78fdf6ae1bbf4dd86ac16c3c5fea9", "ref_doc_id": "f37f44cf-6a50-4f0f-9dfc-5c4d61ed6e7b"}, "fad131bc-10b3-4e2c-854e-b94c70e7dc1e": {"doc_hash": "5cd176284b1aa5ce15d235e3d2a35ea0ec184b00d9cb97d90ccccc3ddaaefe01", "ref_doc_id": "1368e1c6-16ee-4795-a25b-a95225298012"}, "436a2a42-6c2c-4b49-ab08-3a7ff6e2aa79": {"doc_hash": "c97c001490763dd73cbd6c9853e076662dc1841b798ab00dc58a117b78b38063", "ref_doc_id": "8e4ab208-ccaf-4c0d-924c-28ed7f9c6dd9"}, "c3431bb9-2202-4732-b32c-932453fb4b11": {"doc_hash": "7adc6821330f0f6e873c10744b334428f9c2e0493146e9fb9f51b2b88700d79b", "ref_doc_id": "322ce154-6a70-4d4e-bc3e-2db338c6b258"}, "8ff0fcc8-84b0-4b10-98bf-7bff78ff6105": {"doc_hash": "04a9ffa27742c9fbee0f38183e078b8a6c58b11e43b035c538818fd8ac05ffe6", "ref_doc_id": "ffeedfa5-0485-4713-a8b8-be5352df805d"}, "cced6c9b-7764-4c9b-8b4c-61ab9c6fd3ae": {"doc_hash": "c1ab7fbc3c13b8231e60cb190626b429306adf1cef09a000534cc6c638abdf59", "ref_doc_id": "bee0412b-b3c4-47fd-b240-21b5feaeb4ac"}, "fc8f00e9-e33d-40ab-97ce-562f3348f508": {"doc_hash": "1163286e65925971da97979438a07771b73f1606f8f5b6ca5df69b9868b181fd", "ref_doc_id": "bee0412b-b3c4-47fd-b240-21b5feaeb4ac"}, "cae44418-e154-4dc2-b68d-b1ec6635de20": {"doc_hash": "7ceb639d4b782fa44da21a17eb80c1de33d357fbda4a5b1a1c29a271942c37be", "ref_doc_id": "0153d763-c827-49a8-9d7f-4bf6ba531047"}, "e916b8f2-cec9-4ae9-941d-5f3453a9a86e": {"doc_hash": "7a40a03a0a1993e1fb5a34bc55028b55ea9b306e6a8e983fb23e0e2eac90ac3b", "ref_doc_id": "0153d763-c827-49a8-9d7f-4bf6ba531047"}, "ce14c619-d648-48cf-a004-ddc615bf5d4d": {"doc_hash": "a2fd88f670e142277544cce99a0807fc3316463b68c4b4f3c11cee0182f3f678", "ref_doc_id": "0153d763-c827-49a8-9d7f-4bf6ba531047"}}, "docstore/ref_doc_info": {"0e7f7ed6-dd2c-492e-b25a-0a216cd706af": {"node_ids": ["35f8a887-8d06-4f34-b818-b180e9405fa4"], "metadata": {"page_label": "1", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "8b0e3e89-0d16-4579-a5ab-ae7ac473f101": {"node_ids": ["7cd4eb54-733e-4431-9343-a42c8831424c"], "metadata": {"page_label": "2", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "40c6500b-1254-4267-ab2c-1d6ac179494f": {"node_ids": ["b9b8e4ce-cd7b-42fd-8b8a-fac4d9dc9ef2"], "metadata": {"page_label": "3", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "6eb198ce-f6c2-49cd-a09a-bb8180659209": {"node_ids": ["77440028-4e6b-4d39-a0d1-afe59196e5ba"], "metadata": {"page_label": "4", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "3a2f5240-d16f-4c31-a107-eccccaf90dde": {"node_ids": ["2369fd3e-aa24-4778-a0c3-04597c5057fd"], "metadata": {"page_label": "5", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "2e6f775f-d3ec-40bf-a1f5-d6ea3f2a3303": {"node_ids": ["ea7eb0b3-a83e-4ed9-ae7c-c070ed8e8d51"], "metadata": {"page_label": "6", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "b6e9355c-9a05-425e-b5cb-5fbcaea7a89b": {"node_ids": ["4257d4e0-a6ec-45db-aa5c-27aefd1f4f64"], "metadata": {"page_label": "7", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "141d1fb5-dacf-45eb-9d98-940e27f3aaa2": {"node_ids": ["7b853469-8f28-421e-9583-2a1f27e6e19d"], "metadata": {"page_label": "8", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "e4a1b712-c9d9-4f65-b582-d462feccb448": {"node_ids": ["24dc84c8-38b6-486f-a3fb-16846933da08"], "metadata": {"page_label": "9", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "861446fe-d825-47fa-956c-f74f4d730322": {"node_ids": ["1877f1de-e69d-47c6-b3c6-2d4d601031c8"], "metadata": {"page_label": "10", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "05c1bcb4-a4be-4e7d-aa96-ed238f3fe9ae": {"node_ids": ["7526ab4e-c6ab-48e3-af87-0fcab7259c11"], "metadata": {"page_label": "11", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "48ea414d-c6af-4562-b882-803a155b761a": {"node_ids": ["63718a53-7913-4c23-99c7-8d6db65fc2dc"], "metadata": {"page_label": "12", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "1efae18d-ae1d-4f42-9ecc-3630b6e5f147": {"node_ids": ["cfd9666c-fe34-4a10-874f-f3df75ecbaa0"], "metadata": {"page_label": "13", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "3304ff88-a04c-47b3-ad7b-a7b70be04be6": {"node_ids": ["8fd5be10-ad17-4324-a411-2168e1086ce4"], "metadata": {"page_label": "14", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "48a4b216-fe1c-41f2-bb91-d2167685a31a": {"node_ids": ["434d41f4-f4cf-47fa-9958-d75206545a7b"], "metadata": {"page_label": "15", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "6f72aac8-e4ad-4875-aa99-4621e500638d": {"node_ids": ["7b0393cc-969b-40b2-a692-43405cd84a7c"], "metadata": {"page_label": "16", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "ce49db4c-c279-4a36-bb67-1a4e482f7d47": {"node_ids": ["0b461e9d-ebbc-42b5-9218-35df7c8f8fc1"], "metadata": {"page_label": "17", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "918cd242-658d-4dce-b20a-1cdbec0ff4ce": {"node_ids": ["7d3be164-8bbe-4a12-a2c0-757c96a3b200"], "metadata": {"page_label": "18", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "fecfc4d3-7869-4674-bda1-aaa1972715fc": {"node_ids": ["860f2558-712c-40e9-a4c4-e37340f1bcca", "db0575d4-4e4f-4e70-8bfb-57ad69ac0b40"], "metadata": {"page_label": "19", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "0ce131af-0418-4b0c-b581-18dea087bd33": {"node_ids": ["943941ff-1200-4102-b561-5872cafb0abe"], "metadata": {"page_label": "20", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "900de44e-7639-49df-add3-000b06fcc600": {"node_ids": ["8d997c00-1ade-42b5-afc4-e317bf922e6c"], "metadata": {"page_label": "21", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "1f3ca2db-b749-46c7-89ac-009bba6a755b": {"node_ids": ["abadaa34-32ea-43b3-aea3-e4f3a49b7d54"], "metadata": {"page_label": "22", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "0fe0f9ae-393c-4c34-a3c6-7c0b3a8f3111": {"node_ids": ["dd5388ff-a97b-4ae6-bab3-d18cdcf3879e"], "metadata": {"page_label": "23", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "38d6a9cb-503d-423e-adc8-a63cf7f5c5a0": {"node_ids": ["04f45ab3-c799-48b6-ad7d-f030a559f167"], "metadata": {"page_label": "24", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "13c6c55d-232f-4ac9-bb04-ff25df9de458": {"node_ids": ["cd1029ad-3a86-40ad-8447-7cf6b30649a0"], "metadata": {"page_label": "25", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "e260dda8-0825-4524-b466-877aaa8af6d9": {"node_ids": ["7ea7f89a-5aaa-415e-bb18-581e9818d578"], "metadata": {"page_label": "26", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "bc792108-53c1-490c-9e75-1b3e066026f7": {"node_ids": ["8310758c-9655-4a9e-abde-f311bb289f88"], "metadata": {"page_label": "27", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "07818704-808e-46b9-a7b0-9762a45a734c": {"node_ids": ["00179ca1-35c4-4a9d-87c9-91878b48232b"], "metadata": {"page_label": "28", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "dfa3f582-94c8-4371-98f1-ef65ac685138": {"node_ids": ["659a65af-a1bd-40b1-a414-c2cf67a5136b"], "metadata": {"page_label": "29", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "8b5e46e4-6d82-4591-b0d2-02a4cddb69eb": {"node_ids": ["130c24ec-093d-47e6-86b0-aeb7c2599c40"], "metadata": {"page_label": "30", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "da290cdc-d2ce-468f-a622-6d9c9bb2abd6": {"node_ids": ["2882bdd5-0512-49fc-a353-7e72b05fe388"], "metadata": {"page_label": "31", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "e9792f8b-ef6f-4ba1-8f5f-75a59b3f5cd5": {"node_ids": ["fc5221fa-3b37-4928-b7fb-f75e62c1408f"], "metadata": {"page_label": "32", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "e97110f5-6142-4cf3-992b-a5860d149be2": {"node_ids": ["54560577-da4b-4006-94ff-f2ca49994905"], "metadata": {"page_label": "33", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "97115d27-cb40-40f6-b8d4-b940d1fbb302": {"node_ids": ["f56b64a7-f527-4296-b880-98756d6531cb"], "metadata": {"page_label": "34", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "2d58961a-0571-4525-936d-6b48a93435ea": {"node_ids": ["ce474a38-adf2-48ed-93bc-431d8249093d", "2996b545-c7c8-4dca-afc7-26f32ef4b779", "c2b62843-6dcb-4268-a8c7-9bcc036e1fd8"], "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "4a4cf3bc-1f30-41d6-ad0e-3c4d2766941e": {"node_ids": ["856106da-ca0b-4ffc-a3ed-994c6b11616b"], "metadata": {"page_label": "36", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "b5952c43-41a2-47d7-b2ca-c1737bdaeb93": {"node_ids": ["323820fb-677b-47f9-b987-dba191801d42", "8b95b6c8-8e95-426d-a86a-d0b5388153b7"], "metadata": {"page_label": "37", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "bea62208-6772-4058-9f03-3da59893bc45": {"node_ids": ["cbf83524-0535-4353-90b3-a07e2615dd44"], "metadata": {"page_label": "38", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "240bcf4f-e2d4-493a-b8cc-2d31d6dfa3f3": {"node_ids": ["1164f7a9-b54f-43bb-9e38-7806f52e2586"], "metadata": {"page_label": "39", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "a12f41e7-5b11-4a47-a46b-bda98ecc4fb7": {"node_ids": ["a8575b05-e9a3-4a71-a478-44c2d07edf0b"], "metadata": {"page_label": "40", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "f17fec79-7d92-4e31-b263-4b546d50c619": {"node_ids": ["835c77f8-1e01-4680-a939-1cc3b682440e"], "metadata": {"page_label": "41", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "2a55a4fe-af83-46b2-8140-86f11a7707ff": {"node_ids": ["495c3018-429f-4539-ba44-47ae5301449e"], "metadata": {"page_label": "42", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "2a2fb3b0-7524-4546-b2bb-3f5ea854c3ba": {"node_ids": ["24a0081b-bb10-439c-93e5-d8d9c7999762"], "metadata": {"page_label": "43", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "7cbdc3c1-5fea-482b-9014-7b4436534817": {"node_ids": ["dc3f7922-8748-439d-bd7b-dc35f44a8247"], "metadata": {"page_label": "44", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "b365dfd4-fc81-4eba-b7c5-aceec8307475": {"node_ids": ["ef140abc-84bb-45c5-9869-226fcbe92386"], "metadata": {"page_label": "45", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "dcc545cf-a6f2-4c1d-a78c-6d5d457731ef": {"node_ids": ["696d2370-e7ed-4b0f-ba9c-5b3ca5aaa83f"], "metadata": {"page_label": "46", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "dfe261a9-4249-4fb1-a2cc-c4391a005447": {"node_ids": ["ba81e23b-40c2-4fe4-b4b2-71f60798df24"], "metadata": {"page_label": "47", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "f37f44cf-6a50-4f0f-9dfc-5c4d61ed6e7b": {"node_ids": ["762a0144-680d-473e-8f71-d5fc8125edaf"], "metadata": {"page_label": "48", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "1368e1c6-16ee-4795-a25b-a95225298012": {"node_ids": ["fad131bc-10b3-4e2c-854e-b94c70e7dc1e"], "metadata": {"page_label": "49", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "8e4ab208-ccaf-4c0d-924c-28ed7f9c6dd9": {"node_ids": ["436a2a42-6c2c-4b49-ab08-3a7ff6e2aa79"], "metadata": {"page_label": "50", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "322ce154-6a70-4d4e-bc3e-2db338c6b258": {"node_ids": ["c3431bb9-2202-4732-b32c-932453fb4b11"], "metadata": {"page_label": "51", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "ffeedfa5-0485-4713-a8b8-be5352df805d": {"node_ids": ["8ff0fcc8-84b0-4b10-98bf-7bff78ff6105"], "metadata": {"page_label": "52", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "bee0412b-b3c4-47fd-b240-21b5feaeb4ac": {"node_ids": ["cced6c9b-7764-4c9b-8b4c-61ab9c6fd3ae", "fc8f00e9-e33d-40ab-97ce-562f3348f508"], "metadata": {"page_label": "53", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}, "0153d763-c827-49a8-9d7f-4bf6ba531047": {"node_ids": ["cae44418-e154-4dc2-b68d-b1ec6635de20", "e916b8f2-cec9-4ae9-941d-5f3453a9a86e", "ce14c619-d648-48cf-a004-ddc615bf5d4d"], "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}}}, "docstore/data": {"35f8a887-8d06-4f34-b818-b180e9405fa4": {"__data__": {"id_": "35f8a887-8d06-4f34-b818-b180e9405fa4", "embedding": null, "metadata": {"page_label": "1", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0e7f7ed6-dd2c-492e-b25a-0a216cd706af", "node_type": "4", "metadata": {"page_label": "1", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "1c2db4845a5fdcf256b0bb2ce47e928defb762f75264bc56d36b23f0fa745374", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 1\nSTANDARD TREATMENT GUIDELINES\nHypertension\nScreening, Diagnosis, Assessment, and Management of\nPrimary Hypertension in Adults in India\nQuick Reference Guide\nMay 2016\nMinistry of Health & Family Welfare\nGovernment of India\nStandard Treatment Guidelines -Hypertension Page 1\nSTANDARD TREATMENT GUIDELINES\nHypertension\nScreening, Diagnosis, Assessment, and Management of\nPrimary Hypertension in Adults in India\nQuick Reference Guide\nMay 2016\nMinistry of Health & Family Welfare\nGovernment of India\nStandard Treatment Guidelines -Hypertension Page 1\nSTANDARD TREATMENT GUIDELINES\nHypertension\nScreening, Diagnosis, Assessment, and Management of\nPrimary Hypertension in Adults in India\nQuick Reference Guide\nMay 2016\nMinistry of Health & Family Welfare\nGovernment of India", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 818, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7cd4eb54-733e-4431-9343-a42c8831424c": {"__data__": {"id_": "7cd4eb54-733e-4431-9343-a42c8831424c", "embedding": null, "metadata": {"page_label": "2", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8b0e3e89-0d16-4579-a5ab-ae7ac473f101", "node_type": "4", "metadata": {"page_label": "2", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "aaba245787cdaf9c975661938f3fe5cbd33efde49fbfbe3160cceff65d1283d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 2\nTable of Contents\n1.INTRODUCTION:..........................................................................................................................................................3\nKEY RECOMMENDATIONS:.............................................................................................................................................5\n1. SCREENING:........................................................................................................................................................5\n2. CONFIRMATION OF DIAGNOSIS AND CLASSIFICATION OF HYPERTENSION..........................................................7\n3. PATIENT EDUCATION AND ASSESSMENT...............................................................................................................8\n4. MANAGEMENT OF HYPERTENSION: THERAPEUTIC RECOMMENDATIONS.........................................................12\nReview and respond to possible causes of poor response to BP medications........................................................18\n5. FOLLOW UP, MONITORING AND IMPROVING ADHERENCE TO THERAPY...........................................................29\nANNEXURE 1:  PATHWAYS : CLASSIFICATION, ASSESSMENT, MANAGEMENT............................................................31\nANNEXURE 2: LIFE STYLE CHANGES RECOMMENDED FOR PATIENTS DIAGNOSED TO HAVE HYPERTENSION AND FOR\nTHOSE AT RISK OF DEVELOPING HYPERTENSION........................................................................................................38\nANNEXURE 3: FORMULARY..........................................................................................................................................47", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1739, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b9b8e4ce-cd7b-42fd-8b8a-fac4d9dc9ef2": {"__data__": {"id_": "b9b8e4ce-cd7b-42fd-8b8a-fac4d9dc9ef2", "embedding": null, "metadata": {"page_label": "3", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40c6500b-1254-4267-ab2c-1d6ac179494f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "928d19242c30a0b9e5a90e05201d988a4939e0ed13241a1dfd33c34de519c012", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 3\n1.INTRODUCTION:\nHypertension is the number one health related risk factor in India, with the largest contribution to\nburden of disease and mortality (3, 4). It contributes to an estimated 1.6 million deaths,due to ischemic\nheart disease and stroke,out of a total of about 10 million deaths annually in India. Fifty seven percent of\ndeaths related to stroke and 24% of deaths related to coronary heart disease are related to hypertension\n(7).Hypertension is one of the commonest non -communicable diseases in India, with an overall\nprevalence of 29.8% among the adult population , and a higher prevalence in urba n areas (33.8% vs.\n27.6%) according to recent estimates.\nAwareness of hypertension in India is low while appro priate treatment and control among those with\nhypertension is even lower: Hypertension is a chronic, persistent, largely asymptomatic disease. A\nmajority of the patients with hypertension in India are unaware of their condition. This is because of low\nlevels of awareness and the lack of scree ning for hypertension in adults -either as a systematic\nprogramme or as an opportunistic exercise during visits to healthcare providers.\nThe contexts for the screening, diagnosis, evaluation and management of hypertension in India are\ndifferent from countries where awareness of hypertension i n the general population is high and\nscreening for hypertension is a routine part of primary care, practitioners are trained in delivering\nlifestyle interventions and medical management of hypertension, and patients are aware of the need and\nhave the means to adhere to therapy. This is why a standard treatment guideline is being developed for\nthe management of hypertension in the Indian context. The guideline has a primary care focus and a\npublic health approach.\nA public health approach to hypertension in India would involve the five components stated below:\na. Prevention: Promotion of a five point  population wide intervention s on  weight reduction in\nthe obese, increasing exercise levels in the sedentary, decrease in salt , sugar and fat intake,\ncessation of tobacco use, moderation of alcohol use. Increased intake of fruits and vegetables\nin addition to decreased salt intake has the potential to lower blood pressure significantly.\nb. Screening: Screening for hypertension in all adults will involve opportunistic screening of\npeople > 18 years of age at every point of contact with health professionals or allied health\nstaff. Since healthcare facilities may not be accessed by all potential hypertensives, the\nguideline also suggests a targeted screening initiative a t the community level aimed at\ndetection of hypertension in high risk population. Screening will involve BP measurement\nusing a standardized procedure and persons will receive advice and/or referral appropriate to\nthe BP level.\nc. Diagnosis: Diagnosis and eva luation of hypertension will be made at the PHC level which will\nalso serve as the point of follow up for patients diagnosed at higher level facilities. Diagnosis\nand evaluation of hypertension can also occur at all other levels of care. Assessment will focus\non target organ damage related to hypertension, co morbidities like diabetes, and correctable\nrisk factors.\nd. Management including lifestyle changes : Ensure availability of representat ive drugs from a\ncore list of 5 groups of medications \u2013 thiazide diuretics, long acting calcium channel blockers,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3469, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "77440028-4e6b-4d39-a0d1-afe59196e5ba": {"__data__": {"id_": "77440028-4e6b-4d39-a0d1-afe59196e5ba", "embedding": null, "metadata": {"page_label": "4", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6eb198ce-f6c2-49cd-a09a-bb8180659209", "node_type": "4", "metadata": {"page_label": "4", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "eebb34b6f9ae9f2d54d4eb2ec954133784b9c11ea5fd778b47f1e825717e4c8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 4\nlow cost ACE inhibitors, (low cost Angiotensin Receptor blockers in case patients develop side\neffects to ACE inhibitors) , and beta -blockers. Lifestyle changes are a vital componen t of\nmanagement of hypertension, and may be sufficient for control of mild hypertension.\ne. Follow-up, Monitoring Adherence:  Enable a hypertension registry accessible to all healthcare\nproviders in the local public health system, promote adherence to therapy by simplified\nregimens, and monitoring by allied health staff.\nFigure 1: Clinical pathway for hypertension care\n1. SCREEN FOR HYPERTENSION\nScreen For HT (Using Opportunistic & Targeted approaches) By Physicians At All Levels Of Care and\nby Non-Physicians At Community Level Using A Standardized BP Measurement Procedure\n2.CONFIRM DIAGNOSIS OF HYPERTENSION AND CLASSIFY HYPERTENSION\nDiagnosis to be confirmed by  PHYSICIANS, based on at least 2 measurements taken in the clinic or by a\nhealthcare provider on at least 2 visits, which are at least 1-4 weeks apart, (except in the case of\nhypertensive urgencies and hypertensive emergencies)\n3.EDUCATE PATIENTS. ASSESS LIFESTYLE FACTORS, TARGET ORGAN DAMAGE, ASSOCIATED\nCLINICAL CONDITIONS.\nEstablish rapport with patients. Educate them about asymptomatic nature of disease which has risk of\nserious complications which can be prevented by achieving and maintaining target BP by regular therapy.\nEmphasize importance of lifestyle modifications to lower BP and cardiovascular risk.\nAssess lifestyle related and other cardiovascular risk factors, target organ damage, associated clinical\nconditions by using a combination of history, examination and investigations. Assess overall cardiovascular\nrisk. Suspect secondary hypertension in appropriate setting.\n4.MANAGE HYPERTENSION ( LIFESTYLE MODIFICATIONS \u00b1 DRUG THERAPY)\n\uf0b7 Use Lifestyle Modifications in all patients. Initiate Drug therapy with first line antihypertensives\n(calcium channel blockers, ACE Inhibitors (ARBs if indicated), thiazide /thiazide like diuretics in\nGrade 2 /3 HT and in Grade 1 HTwhen indicated.Titrate drug therapy using optimal doses of one\nor more classes of drugs to achieve target BPs.\n\uf0b7 Manage comorbidities like diabetes and associated clinical conditions(heart disease, CVD, CKD)\n\uf0b7 Manage hypertension appropriately in special groups(elderly) and special situations (urgencies and\nemergencies)\n\uf0b7 Use other measures to reduce cardiovascular risk if indicated (statins, aspirin)\n5.FOLLOW UP AND  MAINTAIN ADHERENCE.\nPreferably follow up at Primary Care level with a team based approach.\n\uf0b7 Review BP and advice on adherence. Reassess target organ damage, risk factors periodically.\n\uf0b7 Review and advice on adherence to life style modification.\n\uf0b7 Refer in case of hypertension uncontrolled on 3 drugs, suspected secondary hypertension, and in\nhypertensive emergencies.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2885, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2369fd3e-aa24-4778-a0c3-04597c5057fd": {"__data__": {"id_": "2369fd3e-aa24-4778-a0c3-04597c5057fd", "embedding": null, "metadata": {"page_label": "5", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3a2f5240-d16f-4c31-a107-eccccaf90dde", "node_type": "4", "metadata": {"page_label": "5", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "23e0f3653dd32d5c537ffade681b0c50d66b7e4e891bac5a2e1683d5c0eed417", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 5\nKEY RECOMMENDATIONS:\n1. SCREENING:\n1.1 An ongoing initiative to increase awareness of hypertension as a widely prevalent but\nasymptomatic disease associated with many adverse outcomes like heart attacks,\nstrokes, heart failure, kidney failure. Early diagnosis and effective control of BP can\nsave people from much morbidity, mortality and disability.\n1.2 All adults above the age of 18 years should undergo opportunistic screening by\nhealthcare providers at all points of care in India, either during the course of their\nvisits to the health facilities, or separately as a screening examin ation if requested by\nthe person. Targeted screening at the community level of high -risk groups like adults\nabove 50 years of age, persons with diabetes, obese, smokers, those with existing\ncardiovascular diseases, family history of hypertension, can be un dertaken by trained\nnon-physician staff. a physician or trained non physician staff, using an automated BP\ninstrument or any other validated device, and following a standardized BP\nmeasurement procedure, mentioned in table 1 below.\nTABLE 1- STANDARDIZED BP MEASUREMENT PROCEDURE \u2013\nSTANDARD PROCEDURE FOR BP MEASUREMENT\n1.Patient\npreparation and\nposition\nPatient should be in a relaxed state for 5 minutes before measurement of\nBP. Patient should not have had caffeine in the past 1 hour or smoked in\nthe past 30 minutes.  Patient should be seated comfortably with back\nsupported, with arm at heart level, and legs in an uncrossed position.\n2.Choice of BP\ndevice\nMercury sphygmomanometer or any other device (including electronic\ndigital oscillometric devices) which has been validated using a standard\nprotocol, and has been calibrated regularly.\n3.Cuff size and\nplacement\nThe cuff size should be appropriate for the patient. Length of bladder\nshould be 80% of arm circumference and width should be 40% of arm\ncircumference, and a large adult cuff should be used for an obese patient.\nPatient should not wear any constrictive clothing. Place the midline of the\ncuff over the pulsations of the brachial artery, at a distance of 2 -3 cm\nabove the cubital fossa.\n4. Procedure to\nmeasure systolic\nand diastolic\nblood pressure(\napplicable in\ncase of\nauscultation\nbased BP\nmeasurement)\nPalpate the radial pulse and then inflate the cuff to 30 mm beyond the\ndisappearance of the radial pulse. Deflate the cuff at 2 -3 mm per second\nand record by auscultation with the stethoscope over the brachial artery,\nthe first and the last sounds as the s ystolic and diastolic blood pressure\nrespectively.\nIn oscillometric devices, follow the instructions of the manufacturer, the\nsystolic and diastolic BP will be displayed automatically.\nIf the patient is diabetic or above 65 years measure the BP in supine\nposition,  and 2 minutes after assuming the standing position to check for\npostural hypotension.\n5.No. of\nmeasurements\nand recording\nthe result\nAt least 2 readings should be taken at an interval of 1 minute. If the\nreadings differ by more than 5 mm Hg take s a third reading. The lower of\nthe readings should be taken as the representative SBP and DBP.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3144, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ea7eb0b3-a83e-4ed9-ae7c-c070ed8e8d51": {"__data__": {"id_": "ea7eb0b3-a83e-4ed9-ae7c-c070ed8e8d51", "embedding": null, "metadata": {"page_label": "6", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2e6f775f-d3ec-40bf-a1f5-d6ea3f2a3303", "node_type": "4", "metadata": {"page_label": "6", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "9f28241e1b342f9e92f1fbcc2374d648bf44364ab36225e4dd8ea62afc24aa74", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 6\n1.3 The diagnosis of hypertension should be done by a physician or trained non physician\nstaff, using an    automated BP instrument or any other validated device, and following\na standardized BP measurement procedure.\n1.4. The sources of error during measurement of blood pressure are given in the table below.\nTABLE 2 : SOURCES OF ERROR DURING MEASUREMENT OF BLOOD PRESSURE.\nSource of measurement error (2) Comment (2)\nBack is not supported Diastolic BP may increase by 6 mm\nArm is not at level of heart Dangling the hand unsupported increases BP by 10-12 mm Hg.\nLegs are crossed Systolic BP increases by 2-8 mm Hg\nCaffeine in the last 1 hour Transient increase in BP\nSmoking in the previous 30 mins. s Transient increase in BP\nCuff size not appropriate May overestimate systolic BP by 10-50 mm in obese persons\nin whom a smaller cuff has been used\nRapid deflation greater than 3\nmm/sec\nMay underestimate systolic BP and overestimate diastolic BP\nPatient\u2019s anxiety/ conditional\nresponse to an unusual situation in\nthe presence of a physician\nThis may result in elevated BP readings, which may be normal\nwhen recorded by a nurse or when recorded at home. This\n\u201cwhite coat hypertension\u201d or \u201cisolated office hypertension\u201d\namounted to 32% of hypertensive subjects in population\nbased surveys, and is more prevalent in those with Grade 1\nHT. If the facility is available, then ambulatory or home based\nBP monitoring, can be used to differentiate white coat\nhypertension from true hypertension.\n1.5 Patients who are screened for hypertension should be advised lifestyle measures including\nrestriction of salt intake , advice on diet and exercise in case the person is obese,  stopping\nuse of tobacco and moderating consumption of alcohol to reduce their blood pressure and to\nreduce their overall risk of cardiovascular complications.\nSuggested response to BP readings:\nTABLE 3: SUGGESTED RESPONSE TO INITIAL BP READINGS\nInitial BP reading on screening Advice and Recommendations for Follow up\nSBP mm Hg DBP mm Hg\n<<130 <<85 Advise lifestyle modifications esp. smoking, weight\nreduction if possible : Recheck in 2 years", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2165, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4257d4e0-a6ec-45db-aa5c-27aefd1f4f64": {"__data__": {"id_": "4257d4e0-a6ec-45db-aa5c-27aefd1f4f64", "embedding": null, "metadata": {"page_label": "7", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b6e9355c-9a05-425e-b5cb-5fbcaea7a89b", "node_type": "4", "metadata": {"page_label": "7", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "894ddfdc394dd9f3e1d842c1932e3d887257ef3c3cb689f583d62cbc592b9dc2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 7\n130-139 85-89 Advise lifestyle modifications: Recheck in 1 year\n140-159 90-99 Recheck BP within 1-2 weeks. Advise lifestyle\nmodifications. Refer to nearest health facility within 1\nmonth for diagnosis, assessment.\n160-179 100-109 Recheck BP within 1 week. Advise lifestyle modifications.\nRefer to nearest health facility for confirmation of\ndiagnosis and initiation of treatment.\n>180 >110 Check for any symptoms/signs of any acute target organ\ndamage (assess symptoms and signs referred to in the\nmnemonic \u2018ABCDEFG\u20191mentioned in pathway on\nassessment and management of hypertensive crisis). In\ncases of acute target organ damage, treat as hypertensive\nemergency.\nRefer to PHC/CHC for evaluation and treatment\nimmediately after confirming elevated readings in this\nrange. Initiate therapy before referral, if seen at PHC.\n2. CONFIRMATION OF DIAGNOSIS AND CLASSIFICATION OF HYPERTENSION\n2.1 Diagnosis of hypertension should be made at primary health centres and facilities above that\nlevel using validated and calibrated BP measurement devices and following the standardised\nBP measurement procedure.\n2.2 Diagnosis of hypertension should be based on at least 2 measurements taken in the clinic or\nby a healthcare provider on at least 2 visits, which are at least 1 -4 weeks apart, except in the\ncase of hypertensive urgenc ies and hypertensive emergencies, where hypertension is\ndiagnosed during the first visit itself.Ambulatory blood pressure monitoring and home based\nBP monitoring is not feasible for diagnosis for most patients with hypertension in India and is\ntherefore no t generally recommended. They may be considered where indicated e.g. in\npatients with suspected white coat hypertension, when the expertise and the facility is\navailable.\n2.3 Hypertension should be diagnosed when BP is persistently above a systolic of 140 mm\nand/or diastolic of 90 mm.\n2.4. Patients with hypertension should be classified in the manner given in the table below:\n1 Abbreviation explained -A: Altered consciousness B: Breathlessness C: Chest pain(Ischemic) D: Deficit (weakness of limbs) or\nDecreased Urine output E: Edema F: Fundus if feasible which is showing hemorrhages, exudates, papilledema G: Generalised\nseizures", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2265, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b853469-8f28-421e-9583-2a1f27e6e19d": {"__data__": {"id_": "7b853469-8f28-421e-9583-2a1f27e6e19d", "embedding": null, "metadata": {"page_label": "8", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "141d1fb5-dacf-45eb-9d98-940e27f3aaa2", "node_type": "4", "metadata": {"page_label": "8", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "0ab2d5dff3fe51c7e2d39e93b89eb9eb38579b79de9a9b6a556d40d7bab407d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 8\nTABLE 4: CLASSIFICATION OF HYPERTENSION\nCategory SBP(mm Hg) DBP(mm Hg)\nOptimal <120             and<80\nNormal 120 \u2013 129 and/or          80 \u2013 84\nHigh Normal 130 \u2013 139 and/or           85 \u2013 89\nGrade 1 Hypertension 140 \u2013 159 and/or           90 \u2013 99\nGrade 2 Hypertension 160 \u2013 179 and/or         100 \u2013 109\nGrade 3 Hypertension \u2265 180 and/or \u2265110\nIsolated Systolic\nHypertension\n\u2265 140             and                 < 90\nHypertensive urgency >180             and/or         >110\nSevere asymptomatic hypertension\nwith no evidence of acute target\norgan damage\nHypertensive emergency >180             and /or        >110-120\nSevere hypertension associated with\ncardiovascular (e.g. left ventricular\nfailure, cerebral (e.g. hypertensive\nencephalopathy, stroke),renal (acute\nrenal failure), Grade III-IV retinopathy\n3. PATIENT EDUCATION AND ASSESSMENT", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 892, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "24dc84c8-38b6-486f-a3fb-16846933da08": {"__data__": {"id_": "24dc84c8-38b6-486f-a3fb-16846933da08", "embedding": null, "metadata": {"page_label": "9", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4a1b712-c9d9-4f65-b582-d462feccb448", "node_type": "4", "metadata": {"page_label": "9", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "d1dfc47faad8fcc85f870ae2dc075a318a39b5a715b1d8b63afeaba71e4ab402", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 9\nFigure 2:Patient Education matrix\n3.1 Patient education will consist of awareness on:\na. Nature of disease: Hypertension is an asymptomatic condition which can lead to disabling and\nlife-threatening complications like stroke, heart attack and renal failure\nb. Therapy: Emphasise need for long -term therapy with regularit y of drug intake to prevent\ndamage to target organs and prevent adverse events.\nc. BP control :Educate about the targets for BP control, and encourage patients to monitor\nefficacy of   therapy through regular check -ups which can include home based monitoring of\nBP.\nd. Lifestyle measures : It is important to highlight the important role of lifestyle measures in\nreducing hypertension and reducing risks of cardiovascular disease. (see annexure for details\nof lifestyle modifications)\n3.2 Assessment of patients with hypertension:\n3.2.1 Assessment of a patient with hypertension has the following 5 components\na. Assessing the lifestyle related and other cardiovascular risk factors in patients with\nhypertension and the capability each patient\u2019s capacity or wi llingness to change these\nfactors.\nNature of disease-\nasymptomatic but\nlikely to produce\nserious\ncomplications if\nuncontrolled\nLifelong Therapy-\n(except in some\ncases with Grade 1\nHT)  is useful in\nprevention of\nadverse events\nKnowledge of\ntargets of BP\ncontrol and need\nfor regular\nmonitoring\nNeed to adopt\nLifestyle measures\nto reduce BP and\ncardiovascular risk\nAssess lifestyle factors and other cardiovascular risk factors\nHistory:                              Smoking history\nDietary consumption of salt, saturated fats\nExercise pattern\nAlcohol consumption\nFamily history of premature coronary artery disease\nExamination:                     Weight & Height and calculation of BMI, abdominal\ncircumference\nLaboratory evaluation:    Blood glucose, Lipids", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1894, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1877f1de-e69d-47c6-b3c6-2d4d601031c8": {"__data__": {"id_": "1877f1de-e69d-47c6-b3c6-2d4d601031c8", "embedding": null, "metadata": {"page_label": "10", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "861446fe-d825-47fa-956c-f74f4d730322", "node_type": "4", "metadata": {"page_label": "10", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "a78528704d7739ea300113e0519bf777791343970a89cb3b426e17b992e22974", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 10\nb. Assessing the target organ damage related to hypertension viz. heart failure, left\nventricular hypertrophy, proteinuria, retinopathy.\nc. Assessing the presence of associated clinical conditions like diabetes, kidney disease\nor sym ptomatic cardiovascular disease with angina, myocardial infarction,\ncerebrovascular disease (stroke, TIA) or peripheral arterial disease.\nd. Assessing the clues to a secondary cause of hypertension- see table below:\nAssess target organ damage: Heart (heart failure), Kidney, and Retina\nHistory Breathlessness on effort\nSwelling on feet\nExamination                 Raised Jugular venous pressure, edema, gallops on\nauscultation (heart failure)\nFunduscopic evidence of hypertensive retinopathy-hemorrhages, exudates,\npapilledema\nLaboratory evaluation   ECG: SV1 +RV6 > 3.5 Mv (LVH)\nUrine protein, Serum creatinine\nAssess associated clinical conditions: Myocardial infarction, Stroke, Chronic\nKidney disease\nHistory: Episode of chest pain at rest (Myocardial infarction) in past\nWeakness on one half of body (Stroke) in the past\nExamination: Significant pallor in the presence of HT\u2013 chronic kidney disease\nLaboratory:  S. Creatinine\nECG: Ischemia, infarction, conduction disturbances, arrhythmias (atrial\nfibrillation)\nAssess clues to presence of secondary hypertension\nHistory:\nAbrupt onset of hypertension below the age of 30 years and above the\nage of 60 years (renovascular hypertension)\nParoxysms of palpitations, pain(headache), perspiration(\npheochromocytoma)(1)\nSnoring at night, breathing pauses reported by partner, daytime\nsleepiness (sleep apnoea)\nDrug intake: NSAIDs, Steroids, Oral contraceptive pill\nExamination: mooning of facies, striae: Cushing syndrome\nUnequal pulses: diminished/absent radial pulses- Takayasu\u2019s arteritis\nDiminished & delayed femoral pulse in lower limb: Coarctation of aorta.\nTachycardia and postural hypotension (pheochromocytoma)\nBruit over renal arteries: renal artery stenosis (renovascular\nhypertension)\nLaboratory investigations: Abnormal urinalysis (proteinuria, haematuria),\nelevated creatinine. Abnormal kidneys on USG- renal parenchymal\ndisease, renal artery Doppler for renal artery stenosis.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2225, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7526ab4e-c6ab-48e3-af87-0fcab7259c11": {"__data__": {"id_": "7526ab4e-c6ab-48e3-af87-0fcab7259c11", "embedding": null, "metadata": {"page_label": "11", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "05c1bcb4-a4be-4e7d-aa96-ed238f3fe9ae", "node_type": "4", "metadata": {"page_label": "11", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "3e4a7a4f26087e13db828cd2841ece4c6019b89594243dfc3c95212d23282fef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 11\ne. Assessment of overall cardiovascular risk of a patient . As seen in the table below the\noverall cardiovascular risk increases with the grade of HT, number of risk factors,\npresence of organ damage, diabetes, symptomatic cardiovascular disease or chronic\nkidney disease.\nGrade 1 HT Grade 2 HT Grade 3 HT\nNo risk factor Low risk Moderate risk# High\u00a7 risk\n1-2 risk factor* Moderate\nrisk\nModerate to\nhigh\nHigh risk\n>3 risk factor* Moderate\nto High risk\nHigh High risk\nTarget Organ damage,\nDM, CKD stage 3\nHigh risk High risk Very high risk\nSymptomatic CVD(\nstroke, coronary artery\ndisease), diabetes with\norgan damage,\nCKD>stage 4\nVery high\nrisk\nVery high risk Very high risk\n# 20-30%  risk of CV event over 10 years \u00a7 >30% risk of CV event over 10 years *Risk\nfactors(apart from hypertension) : age ( > 55 years in men, 65 years in women), male gender,\ndiabetes mellitus,smoking,obesity(including abdominal obesity ), dyslipidemia (High LDL, Low\nHDL,High TG) , impaired fasting glucose(FPG 100 -125 mg/dl) , family history of premature\ncoronary artery disease.\n3.2.2 Pragmatic approach to assessment of hypertensives in India: In the context of the Indian public\nhealth system, we suggest an approach which balances the needs of patients  and the resources available\nat various levels and outline a pragmatic approaches to assessment \u2013 essential assessment in all patients\nwith  Grade 1 HT, desirable assessment in those with grade 2 HT or those with diabetes and/or\nproteinuria, and comprehensive assessment in those with Grade 3 HT, or those with diabetic\ncomplications, CKD, heart failure, or with a suspicion of secondary hypertension are suggested. This\napproach also takes into account the fact that some investigations like ECG for left ventricular\nhypertrophy have poor sensitivity , while there is insufficient evidence that a routine ophthalmoscopic\nexamination is required for all patients with hypertension. On the other hand, patients with diabetes,\nsymptomatic cardiovascular disease, smokers, obese, and those with proteinuria, which are all\nassociated with greater cardiovascular risk can be identified even at the level of a primary health centre\nusing a combination of clinical features (history and clinical examination) and investigations. Assessment\nof lipids is desirable in patients with hypertension, with a higher yield in those who are diabetics, obese\nand have cardiovascular disease. Patients can be referred to the community health centre for evaluation\nof lipids, but the need is not urgent.\nEssential assessment\nShould be done in all patients attending primary care facilities, also in patients with Grade 1 hypertension\nHistory and physical examination for risk factors (smoking, obesity, diet and exercise patterns, family history of\npremature CVD), clinical cardiovascular disease (angina, heart failure, stroke)\nFasting capillary blood(FCG) or fasting plasma glucose (FPG). FCG > 126 mg/dl or FPG >126 mg/dl is abnormal and\nsuggestive of diabetes. Abnormal fasting capillary glucose needs to be checked against a fasting plasma glucose\nobtained in the laboratory", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3149, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "63718a53-7913-4c23-99c7-8d6db65fc2dc": {"__data__": {"id_": "63718a53-7913-4c23-99c7-8d6db65fc2dc", "embedding": null, "metadata": {"page_label": "12", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "48ea414d-c6af-4562-b882-803a155b761a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "43c452da790dd26bcb7394d0ca571644ce4a6845de6e99ef31c56cd4175e23ce", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 12\nDesirable assessment\nDesirable in patients with Grade 2 hypertension and above, with family history of premature cardiovascular\ndisease, in patients with diabetes and in patients with proteinuria\nEssential assessment plus\nSerumcreatinine: Abnormality more often seen in patients with severe hypertension, diabetic nephropathy,\nchronic kidney disease or occasionally in patients on ACE inhibitors.\nLipids: more often abnormal in patients who are obese, in diabetics, in patients with cardiovascular disease.\nCommonest abnormality in India is low HDL, increased triglycerides\nECG: Low sensitivity for detection of LVH. LVH if present however indicates increased cardiovascular risk. LVH\nwith strain strong predictor of heart failure.  May yield evidence of ischemic heart disease, conduction system\ndisturbance or arrhythmias.\nUrinalysis for proteinuria: Presence of proteinuria doubles the risk of morbidity and mortality for a certain BP and\nis an independent predictor of all-cause mortality in hypertension.\n3.3   Screening for diabetes (which is to be available at all health facilities under the free\ndiagnostics initiative) is an i ntegral part of evaluation of hypertension because of the common\nassociation of hypertension and diabetes. The care of diabetes should be integrated with\nmanagement of hypertension.\n3.4   All patients should be asked about tobacco use and advised to stop it.\n4. MANAGEMENT OF HYPERTENSION: THERAPEUTIC RECOMMENDATIONS\n4.1. Overall aim : The overall aim of the management of hypertension is not only reduction of BP to\ntarget levels but also to lower the cardiovascular risk of the patient. Management of hypertension should\nbe tailored to the individual and his or her circumstances.\nComprehensive evaluation: In patients with Grade 3 hypertension, patients with CKD, heart failure\nDesirable evaluation plus\nHistory and physical examination: exclude signs of secondary hypertension\nSerum sodium and potassium: hypokalemia clue to secondary hypertension (renovascular, primary\nhyperaldosteronism)\nUltrasound kidney: for evidence of CKD\nEchocardiography: in case of suspected heart failure (on basis of history, physical examination)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2220, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cfd9666c-fe34-4a10-874f-f3df75ecbaa0": {"__data__": {"id_": "cfd9666c-fe34-4a10-874f-f3df75ecbaa0", "embedding": null, "metadata": {"page_label": "13", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1efae18d-ae1d-4f42-9ecc-3630b6e5f147", "node_type": "4", "metadata": {"page_label": "13", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "8a4cef343626413a6edf3ed0fcfb19d5cba7ed25407be8ba0af38c3e9c85ffe1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 13\n4.2. Lifestyle modifications\n4.2.1 Lifestyle measures including adopting a heart -healthy diet with reduced salt and\nsaturated fat intake, stopping use of tobacco products , regular exercise and reduction\nof body weight in those who are obese, are part of management o f all patients with\nhypertension.\n4.2.1.1. These lifestyle measures may be sufficient for treatment of Grade 1\nhypertension, may reduce the doses required for control of hypertension, and\nwill also reduce the cardiovascular risk in all grades of hypertension.\n4.2.1.2 A trial of lifestyle measures should be monitored for 1 -3 months\nfollowing diagnosis of Grade 1 hypertension. The lower range of\ndurations should be considered in the presence of other risk factors like\nage, obesity, lipid levels, and smoking status.\n4.3 Initiation of drug therapy\n4.3.1 Drug therapy is indicated in patients with Grade 1 hypertension with\n\u2022 Any sign of target organ damage (LVH on ECG, proteinuria on urinalysis,\nhypertensive retinopathy on fundus examination).\n\u2022 Any evidence of coronary artery disease, congestive heart failure,\ncerebrovascular disease , peripheral arterial disease (clinical cardiovascular\ndisease)\n\u2022 Diabetes\n\u2022 Presence of chronic kidney disease\n\u2022 Patients with 3 or more risk factors 2 (including age, gender, smoking, obe sity,\ndyslipidemia, diabetes, impaired fasting glucose , family history of premature\ncoronary artery disease).\n4.3.2. Drug therapy in patients with grade I hypertension uncomplicated by any organ\ndamage, without coexisting diabetes mellitus, clinical cardiovascula r disease , or\nmultiple cardiovascular risk factors should be initiated after a trial of 1-3 months of\nlifestyle modifications.\n4.3.3. Drug therapy is indicated in all patients with Grade 2 and Grade 3   hypertension\nand should be combined with lifestyle measures.\n2 Age > 55 in men, >65 in women; Male gender; smoking; diabetes; obesity including abdominal obesity; impaired fasting\nglucose ( FBS 100-125 mg/dl); dyslipidaemia (high LDL, high TG, low HDL); family history of prematur e coronary artery disease", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2128, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8fd5be10-ad17-4324-a411-2168e1086ce4": {"__data__": {"id_": "8fd5be10-ad17-4324-a411-2168e1086ce4", "embedding": null, "metadata": {"page_label": "14", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3304ff88-a04c-47b3-ad7b-a7b70be04be6", "node_type": "4", "metadata": {"page_label": "14", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "e433d195969c85f44c6c9428073fd91349f3ec8d4d1449ab253c17b57e83070a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 14\n4.3.3.2.Drug therapy is initiated in patients with Grade 2 hypertension on\nconfirmation of the diagnosis on repeat BP measurements in the visits subsequent\nto the initial visit when Grade 2 HT was first detected.\n4.3.3.3.Drug therapy in patients with Grade 3 hypertension is initiated after repeat\nmeasurements in the initial visit confirm the severe elevation of the blood\npressure.\n4.4. Treatment goals for management of hypertension:\n4.4.1 The current target for control of BP for patients under 80 years of age should be less than\nsystolic blood pressure less than 140 mm and diastolic blood pressure less than 90 mm.\n4.4.2 The current target for control of BP for patients 80 years or older should be less than 150\nmm systolic and less than 90 mm diastolic.\n4.4.3 A recent trial (SPRINT trial) in non-diabetic population at high cardiovascular risk has\nshown a reduction in cardiovascular mortality in patients in the intensive treatment group\nwhere the goal BP was less than 120 mm systolic and 80 mm diastolic. However this was\naccompanied b y more than 2 fold increased frequency of serious adverse events and\nincrease in serum creatinine. Based on the currently available evidence we do not\nrecommend this lower target generally for physicians and patients in India, except for\nindividual patient s and physicians in situations who have agreed upon these targets and\nwhere close monitoring for adverse effects is feasible.\n4.4.4 Current evidence based on trials of BP targets of <130 mm and < 85 mm diastolic in\npatients with diabetes have failed to show sig nificant overall benefit on cardiovascular\ndisease outcomes, and have been accompanied by increased frequency of serious adverse\nevents. Therefore we currently recommend the standard BP target of <140 mm systolic\nand <90 mm in patients with diabetes in India.\nTARGET\n< 80 years: Systolic BP < 140mm Hg\nDiastolic BP < 90mm Hg\n>80 years: Systolic BP < 150mm Hg\nDiastolic BP < 90mm Hg\nDiabetics: Systolic BP < 140mm Hg\nDiastolic BP <90mm Hg", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2057, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "434d41f4-f4cf-47fa-9958-d75206545a7b": {"__data__": {"id_": "434d41f4-f4cf-47fa-9958-d75206545a7b", "embedding": null, "metadata": {"page_label": "15", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "48a4b216-fe1c-41f2-bb91-d2167685a31a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "f693089cf88b8f9ccc2239997309852009c2bf726f625dd47ff9a98f21de1a86", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 15\n4.5 Key recommendation: Classes of antihypertensive drugs & preferred choices\n4.5.1            The primary issue in treatment of hypertension is reduction of cardiovascular risk by\neffective control of blood pressure. Overall the benefits of antihypertensive treatment are\ndue to lowering of blood pressure rather than choice of therapy. Many patients will\nrequire more than one drug for control of hypertension.\n4.5.2.         All classes of drugs - calcium channel blockers, ACE inhibitors/ARBs, d iuretics; beta-blockers\nhave approximately the same efficacy on lowering of blood pressure, and on outcomes,\nalthough beta -blockers have been associated with lesser protection against strokes. All\ncombinations of drugs are not however similarly efficacious, and some are preferred.\n4.5.3.      The differen t classes of drugs have differing side effect profiles and requirements for\nmonitoring, which may influence their use and prescription in the health system.\n4.5.4 In the absence of any associated clinical conditions (noted below) providing a compelling\nindication for the use of a particular drug , a long acting calcium channel blocker, a low\ndose thiazide diuretic, or a  low cost ACE inhibitor may be used as the initial\nantihypertensive drug.\n4.5.5. The presence of associated clinical conditions (diabetes, clinical cardiovascular disease, chronic\nkidney disease) in a patient may provide compelling indication for the use of specific\nclasses of drugs.\n4.5.5.1.         Preferred drugs for treatment of patients with diabetes and hypertension are\nACE inhibitors, especially in those with proteinuria.  Calcium channel blockers\n/low dose diuretics may be used in addition if required to achieve control.\n4.5.5.2 Preferred drugs for patients with heart failure and hypertension are ACE inhibitors,\ndiuretics (including loop diuretics) and beta-blockers.\n4.5.5.3 Preferred drugs for patients with coronary artery disease and hypertension are\nbeta-blockers, ACE Inhibitors or calcium channel blockers.\n4.5.6 The specif ic drugs within these classes recommended on the basis of availability and\naffordability include amlodipine, (a long acting calcium channel blocker ); enalapril or\nlisinopril, (ACE inhibitor); low dose hydrochlorothiazide , (thiazide) or chlorthalidone\n(thiazide like diuretic) and if required, losartan, (a low cost angiotensin II receptor blocker).\n4.5.7 Angiotensin receptor blockers have a mode of action, efficacy and indications similar to ACE\ninhibitors, but are currently more expensive than them.  They should therefore be used in\nthe place of ACE inhibitors, in case there are side effects with ACE inhibitors like cough,\nangioedema.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2723, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b0393cc-969b-40b2-a692-43405cd84a7c": {"__data__": {"id_": "7b0393cc-969b-40b2-a692-43405cd84a7c", "embedding": null, "metadata": {"page_label": "16", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6f72aac8-e4ad-4875-aa99-4621e500638d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "07890e70b16e1c165609ae77d9957acfc19066b1a692f09572bd05de8f4816b0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 16\nClinical condition Drug to be preferred as\nfirst drugs\nSecond drug if needed\nto achieve BP control\nThird drug if needed to\nachieve BP control\nIsolated systolic hypertension\n( elderly)\nCCB/Thiazide Diuretic ACE Inhibitor* Thiazide diuretic + ACE\nInhibitor*+ CCB\nHypertension and diabetes ACE inhibitor* CCB or thiazide diuretic ACE inhibitor* + CCB+\nthiazide diuretic\nHypertension and chronic\nkidney disease(defined as\nalbuminuria or an eGFR< 60\nml/min/1.73 m2 for > 3\nmonths)\nACE inhibitor*where close\nclinical and biochemical\nmonitoring is possible.\nOtherwise CCB  may be\npreferable\nCCB or thiazide diuretic\n(loop diuretic if eGFR is\nbelow 30 ml/min)\nACE inhibitor*\n+CCB+ thiazide diuretic\nHypertension and previous\nmyocardial infarction\nBB, ACE Inhibitor* CCB or diuretic\nHypertension associated with\nheart failure\nThiazide/ loop diuretic+ ACE  Inhibitor*+BB#+ Spironolactone\nHypertension associated with\nprevious stroke\nACE inhibitor* Diuretic or CCB ACE Inhibitor* +CCB+\ndiuretic\nTable 9:  Clinical conditions which may be associated in a patient with hypertension and the drugs to be\npreferred\n*Angiotensin receptor blockers (ARBs) may be used for this indication if there is intolerance to ACE inhibitors (cough,\nangioedema)Abbreviations: ACE inhibitor: angiotensin converting enzyme inhibitor; CCB, calcium channel blocker; BB, beta -\nblocker.Notes: Examples of representative drug s: ACE inhibitors - Enalapril, Calcium channel blockers -Amlodipine, Thiazide\ndiuretic- Hydrochlorothiazide, Beta -blocker- Atenolol.# In patients with heart failure the preferred beta -blockers are\nmetoprolol, carvedilol, bisoprolol.\n\u00a7 Source: adapted from ref.(21)\nTable 10: Compelling and possible contraindications to the use of antihypertensive drugs#\nDrug Compelling contraindication Possible contraindication\nDiuretics Gout Metabolic syndrome, glucose\nintolerance, hypokalemia,\nhypercalcemia\nBeta-blockers Asthma, AV block (grade 2 or 3) Metabolic syndrome, glucose\nintolerance, chronic obstructive\npulmonary disease\nCalcium channel\nblockers(dihydropyridines)\nTachyarrhythmia, heart failure\nCalcium channel blockers(non-\ndihydropyridines)\nAV block (Grade 2 or 3),severe left\nventricular dysfunction, heart failure\nACE inhibitors Pregnancy\nHyperkalemia\nBilateral renal artery stenosis\nWomen with childbearing potential\nAngiotensin receptor blockers Pregnancy\nHyperkalemia\nBilateral renal artery stenosis\nWomen with childbearing potential\nMineralocorticoid receptor\nantagonists ( e.g. spironolactone)\nAcute or severe renal failure\n(eGFR<30 ml/min)\nAbbreviations: AV, atrioventricular; eGFR, estimated glomerular filtration rate", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2673, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0b461e9d-ebbc-42b5-9218-35df7c8f8fc1": {"__data__": {"id_": "0b461e9d-ebbc-42b5-9218-35df7c8f8fc1", "embedding": null, "metadata": {"page_label": "17", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ce49db4c-c279-4a36-bb67-1a4e482f7d47", "node_type": "4", "metadata": {"page_label": "17", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "719c480ad2b232b2f6070261800bc88c696b9041b411e05ea6bd967a38d03ab0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 17\nSource: ref. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the\nTask Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European\nSociety of Cardiology (ESC). Blood pressure. 2013;22(4):193-278.\nKEY RECOMMENDATIONS\n4.6 The treatment regimen and the use of combinations:\n4.6.1 In patients with Grade 1 or Grade 2 hypertension, therapy can be initiated with one drug (CCBs,\nACE inhibitors, thiazide diuretics)   in combination with lifestyle modifications (Step 1 in table 13).\nAverage initial doses can be 5 mg of amlodipine, 5 mg of enalapril and 12.5 mg of\nhydrochlorothiazide.\n4.6.2 In patients with Grade 3 hypertension , the therapy should be initiated with two drugs, in\ncombination with lifestyle modificat ions ( Step 2 in table 13). The combinations can be calcium\nchannel blocker (amlodipine) + ACE inhibitor (enalapril) or calcium channel blocker (amlodipine) +\nthiazide diuretic ( hydrochlorothiazide) or ACE inhibitor (enalapril) + thiazide diuretic\n(hydrochlorothiazide).\n4.6.3 The dose of drugs can be increased or a new drug added at approximately 2 - to 4-week intervals.\nThis frequency can be faster or slower depending on the clinical circumstances of the patient and\nthe judgment of the practitioner.\n4.6.4   The addition of a new drug in patients with Grade 1 or Grade 2 hypertension may be preferable to\nmaximising the dose of the initial drug. In case a calcium channel blocker (amlodipine) has been\nused as initial therapy, the add -on drug can be ACE inhibitor (enalapril) or a thiazide diuretic.\nSimilarly if ACE inhibitors have been used as initial therapy, a calcium channel blocker or a diuretic\ncan be used as add on the rapy. When amlodipine is used as an add -on therapy, the initial dose\nused should be 2.5 mg. Similarly if an ACE inhibitor like enalapril is added to a diuretic, the initial\ndose used may be 2.5 mg to avoid hypotension.\n4.6.5. If the second drug in a usual dose also fails to reduce BP to target levels then the third class of\ndrug previously unutilised should be added (Step3 in table 13). An optimal 3 drug combination in\ncase it is required is a calcium channel blocker with a low dose thiazid e diuretic and an ACE\ninhibitor (e.g. amlodipine+ enalapril+ hydrochlorothiazide).\n4.6.6. The preferred 2 drug combinations are combination of calcium channel blockers with ACE\ninhibitors, ACE inhibitors with low dose diuretics, and calcium channel blockers with low dose\ndiuretics.\n4.6.7. Prescription of a single pill combination of antihypertensive drugs in a defined proportion may be\nconsidered if available, after BP has been stabilised with a dose of two drugs given singly in the\nsame proportion.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2821, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7d3be164-8bbe-4a12-a2c0-757c96a3b200": {"__data__": {"id_": "7d3be164-8bbe-4a12-a2c0-757c96a3b200", "embedding": null, "metadata": {"page_label": "18", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "918cd242-658d-4dce-b20a-1cdbec0ff4ce", "node_type": "4", "metadata": {"page_label": "18", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "3a89c26639453a8d989acc1047caecb61f5cec5567bb67803ccf157f8c75d692", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 18\n4.6.8. The practitioner should aim for patients to r each target BP levels with an effective treatment\nregimen, whether 1, 2, or 3 drugs, within 6 to 8 weeks.\n4.6.9. Add-on drugs for control of BP drugs should be added at intervals of 2-4 weeks.\n4.6.10. Negative recommendation: ACE Inhibitors should not be combined with A ngiotensin receptor\nblockers.\n4.6.11. Avoid prescribing a combination of beta -blockers and diuretics as they can increase the risk of\ndiabetes mellitus in those at risk, e.g. persons with impaired glucose tolerance or obesity and\nmetabolic syndrome.\n4.6.12. If the BP is not controlled despite use of 3 anti -hypertensives, then the hypertension should be\ntermed resistant and the patient should be referred to a specialist at the medical college for\nfurther evaluation and management.\nThe management of hypertension is shown in text form in the box below and the doses of the\ndrugs to be used are mentioned in table 12.\nReview and respond to possible causes of poor response to BP medications\n4.7. Key  Recommendations:\nWhen a patient does not respond to two drugs given in full doses, the physician should review the\nunderlying issues -related to\n\uf0a7 BP measurements,\n\uf0a7 poor adherence to drug and lifestyle modifications, including stoppage of\nmedicines due to belief in other systems of medicine\n\uf0a7 suboptimal treatment regimens,\n\uf0a7 presence of associated conditions,\n\uf0a7 use of non -antihypertensive drugs which can interfere with the action of anti -\nhypertensives, and\n\uf0a7 Consider the possibility of secondary hypertension.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1599, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "860f2558-712c-40e9-a4c4-e37340f1bcca": {"__data__": {"id_": "860f2558-712c-40e9-a4c4-e37340f1bcca", "embedding": null, "metadata": {"page_label": "19", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fecfc4d3-7869-4674-bda1-aaa1972715fc", "node_type": "4", "metadata": {"page_label": "19", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "bc4bfb773df7d4a2a4d21ef77bb83fe4ba5fdbee5fa93e546b4bccb5122e47fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db0575d4-4e4f-4e70-8bfb-57ad69ac0b40", "node_type": "1", "metadata": {}, "hash": "d118a0d3d665d4bffae80f37ca1f808344b54689bf7b19adcfefba14402f1581", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Standard Treatment Guidelines -Hypertension Page 19\nMANAGEMENT OF HYPERTENSION - target BP <140/90 mmHg in those < 80 years, 150/90 in those over\n80 years.\nALL PATIENTS REQUIRE LIFE-LONG LIFESTYLE MODIFICATION\nDietary change to Heart-healthy diet\u2013 salt 5 6 g/day, low-fat diet\nRegular exercise\nMaintain  weight \u2013 target BMI 18.5-22.9 kg/m2\nStop smoking\nPatients with Grade 1 hypertension may require only lifestyle modification, which should be tried for 3\nmonths.\nGRADE 1 HYPERTENSION (SBP 140-159 mm, DBP 90-99mm) with\nInadequate control after 3 months of lifestyle modification OR more than 3 risk factors:\nMale,Age: men >55 years, women>65 years,smoking, obesity, including abdominal obesity\nDyslipidaemia,impaired fasting glucose, family history of early\ncoronary artery disease\nDrug therapy \u2013 A or C1 or D\nAdd second drug - A+C or C+D or A+D if response not adequate within 2-4 weeks\nAdd third drug \u2013 A+C+D if response not adequate within 2-4 weeks\nGRADE 2 HYPERTENSION (SBP 160-179, DBP 100-109)\nDrug therapy \u2013 A or C or D\nAdd second drug - A+C or C+D or A+D if response not adequate within 2-4 weeks\nAdd third drug \u2013 A+C+D if response not adequate within 2-4 weeks\nGRADE 3 HYPERTENSION (SBP \u2265180, DBP \u2265110)\nUse two drugs - A+C or C+D or A+D\nAdd third drug \u2013 A+C+D if response not adequate within 2-4 weeks\nALL GRADES OF HYPERTENSION WITH ASSOCIATED CLINICAL CONDITIONS\nCAD: coronary artery disease - B+A2, C\nCHF: congestive heart failure - D+A+B, MRA\nCKD: chronic kidney disease \u2013 A or  C or  D3\nDM: diabetes mellitus \u2013 A or C, D\nDrugs are added only if they are required to achieve the target BP of <140/90 mm Hg (in patients <80 years old) or\n<150/90 mm Hg (in patients >80 years of age)\nAbbreviations: CAD: coronary artery disease, CHF: congestive heart failure, CKD: chronic kidney disease, DBP:\ndiastolic blood pressure, DM: diabetes mellitus, SBP: systolic blood pressure, TOD: target organ damage.\nDrug classes: A: Angiotensin converting enzyme (ACE) inhibitors, (e.g. enalapril) or Angiotensin II receptor\nblockers (ARBs) (e.g. losartan) if intolerance to ACEinhibitors, B: Beta-blockers (e.g. atenolol), C: Calcium channel\nblockers (e.g. amlodipine), D: thiazide diuretics (e.g. hydrochorothiazide), MRA: mineralocorticoid receptor\nantagonist (e.g. spironolactone).\nDrug doses: Doses for initiation of therapy : A : enalapril 5 mg; B: Atenolol 50 mg; C: Amlodipine 5 mg ( 2.5 mg\nin elderly);  D:  Hydrochlorthiazide/Chlorthalidone 12. 5 mg.\nAdd-on doses: A : enalapril 5 mg (reduce in elderly or in those on diuretics), C: amlodipine 2.5 mg, D:\nhydrochlorthiazide 12.5 mg\nMaximal doses: A : enalapril 20-40 mg; B: Atenolol 100 mg C: Amlodipine 10 mg; D: Hydrochlorthiazide: 25 mg\nFootnotes :\n1 Calcium channel blockers are antihypertensives of choice in the elderly (> 60 years).\n2Patients with CAD and history of myocardial infarction should receive both beta-blockers and ACE inhibitors\n3 Patients with CKD may require loop diuretics if the glomerular filtration rate is low. Patients on ACE inhibitors will\nrequire monitoring of serum creatinine and potassium.\nBased on references: Hypertension: Clinical management of primary hypertension in adults NICE guidelines [CG127].\nNational Institute for HealthCare Excellence; 2011 Weber MA, Schiffrin EL, White WB, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3286, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "db0575d4-4e4f-4e70-8bfb-57ad69ac0b40": {"__data__": {"id_": "db0575d4-4e4f-4e70-8bfb-57ad69ac0b40", "embedding": null, "metadata": {"page_label": "19", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fecfc4d3-7869-4674-bda1-aaa1972715fc", "node_type": "4", "metadata": {"page_label": "19", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "bc4bfb773df7d4a2a4d21ef77bb83fe4ba5fdbee5fa93e546b4bccb5122e47fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "860f2558-712c-40e9-a4c4-e37340f1bcca", "node_type": "1", "metadata": {"page_label": "19", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "4eabe9d9306cf359ecf0adb732cff0793ae24709cabe7e0d0c9af8ddcde6b77c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2Patients with CAD and history of myocardial infarction should receive both beta-blockers and ACE inhibitors\n3 Patients with CKD may require loop diuretics if the glomerular filtration rate is low. Patients on ACE inhibitors will\nrequire monitoring of serum creatinine and potassium.\nBased on references: Hypertension: Clinical management of primary hypertension in adults NICE guidelines [CG127].\nNational Institute for HealthCare Excellence; 2011 Weber MA, Schiffrin EL, White WB, et al. The Journal of Clinical\nHypertension. 2014;16(1):14-26.", "mimetype": "text/plain", "start_char_idx": 2797, "end_char_idx": 3342, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "943941ff-1200-4102-b561-5872cafb0abe": {"__data__": {"id_": "943941ff-1200-4102-b561-5872cafb0abe", "embedding": null, "metadata": {"page_label": "20", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0ce131af-0418-4b0c-b581-18dea087bd33", "node_type": "4", "metadata": {"page_label": "20", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "8572139bd7c2a49237cc7503a47a9dabc9dc6de3bc4dc9d74e45a2d4c561dd4b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 20\nTable 12: Initial and maximal doses for initiation and titration of therapy for Indian patients\nwith hypertension: (source: adapted from ref (24), (70) and product monographs listed at health\nCanada www.health-sc.gc.ca)\nDrug class Low dose in\ncertain\nsituations\nUsual Initial\ndose\nsuggested for\nIndian\npatients with\nhypertension\nMaximal\ndosage\nsuggested for\nIndian patients\nwith\nhypertension\nDoses per\nday\nCalcium channel blockers\nDihydropyridines\nAmlodipine 2.5 mg* 5 mg 10 mg 1\nAngiotensin converting enzyme inhibitors\nEnalapril 2.5 mg\u00a7 5 mg 10-20 mg 1-2\nLisinopril 5 mg 10 mg 1\nAngiotensin receptor blockers\nLosartan 25 mg # 50 mg 100 mg 1-2\nTelmisartan 40 mg 80 mg 1\nDiuretics\nThiazides 1\nHydrochlorothiazide 12.5 mg 25 mg 1\nThiazide-like\nChlorthalidone 12.5 mg 25 mg 1\nBeta-blockers\nAtenolol 25 mg 50 mg 100 mg 1\nMetoprolol succinate 50 mg 100 mg 2\n*Reduce dose of amlodipine to 2.5 mg once a day when it is started in low body weight elderly patients,\nand when amlodipine is added to another antihypertensive medication.\n\u00a7 Reduce dose to enalapril 2.5 mg when it is used in elderly (>65 years) and when t he patient has been\non diuretic therapy.\n# Use dose of 25 mg in patients less than 50 kg (Canadian labelling)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1263, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8d997c00-1ade-42b5-afc4-e317bf922e6c": {"__data__": {"id_": "8d997c00-1ade-42b5-afc4-e317bf922e6c", "embedding": null, "metadata": {"page_label": "21", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "900de44e-7639-49df-add3-000b06fcc600", "node_type": "4", "metadata": {"page_label": "21", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "09929853fda6b12ef3f35873d2a86b5211e2f76938b6da24577ddbb4e94e0bb0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 21\nInitiation\nwith single\ndrug\nStep 1\nInitiation with 2 drugs or titration of drugs in a patient\nnot controlled on a single drug : Step 2\nUse of three\ndrugs in a\npatient not\ncontrolled\nwith 2 drugs\nStep 3\nCCB\n(amlodipine)\nDiuretic\n(hydrochlorothiazide)\nACE\ninhibitor\n(enalapril)\nACE\ninhibitor\nEnalapril 5\nmg\nOr\nEnalapril 5 mg+\nAmlodipine 2.5\nmg , later raise to\n5 mg\nEnalapril 5 mg  +\nHydrochlorothiazide\n12.5mg\nEnalapril 10\nmg (less\npreferred\nstrategy)\nACE inhibitor\n(Enalapril\n5/10mg )\n+\nCCB\nAmlodipine\n5/10 mg)\n+\nThiazide\nHydrochlorot\nhiazide\n12.5mg/25\nmg)\nCCB\nAmlodipine 5\nmg\nOr\nAmlodipine 10\nmg\n(less preferred\nstrategy)\nAmlodipine 5 mg +\nThiazide 12.5 mg\nAmlodipine\n5 mg\n+Enalapril 5\nmg\nThiazide\ndiuretic\nHydrochloro-\nthiazide 12.5\nmg\nDiuretic + CCB\n(Amlodipine 2.5\nmg, later 5 mg)\nHydrochlorothiazide\n25 mg (less preferred\nstrategy)\nHydrochlor\nothiazide\n12.5 mg\nEnalapril\n2.5 mg ,\nlater 5 mg\nTable 13: Medication pathway in this guideline evolving from Step 1 (single drug) to Step 2\n(two drugs) to Step 3", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1052, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "abadaa34-32ea-43b3-aea3-e4f3a49b7d54": {"__data__": {"id_": "abadaa34-32ea-43b3-aea3-e4f3a49b7d54", "embedding": null, "metadata": {"page_label": "22", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1f3ca2db-b749-46c7-89ac-009bba6a755b", "node_type": "4", "metadata": {"page_label": "22", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "7b59d2f229e5bcb890a6530980661ed8d41c4add66fe9e4bc8eba177bd633b5d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 22\nWhen a patient is no t responding to BP medications, as determined by persistently high BP\nreadings on repeat visits, the physician should pay attention to the following factors:\n1. Issues related to BP measurement in the clinic: This may include \u201cwhite coat effect\u201d\nbecause of which the clinic based BP measurements by a doctor may be higher than\nthose obtained at home or by another healthcare provider. Improper size of cuff and\nimproper technique may also give falsely elevated BP readings.\n2. Adherence to medications: In a chronic disease, which are asympto matic, patients often\nmiss doses or even discontinue medications, and the regularity of drug intake should be\nenquired about from the patient and their relatives. The reasons for non -adherence\nshould also be explored which may include doubts about the diag nosis, belief in lifestyle\nmodifications being sufficient, cost of therapy, or si de effects related to medicines.\nBelief in other systems of medicine may also lead to stoppage of medicines\n3. Adherence to lifestyle modifications: Excessive salt intake, excess ive alcohol\nconsumption, tobacco use, obesity all can contribute to poor control of hypertension.\n4. Suboptimal treatment regimens: This can be the result of low doses, or use of\ninappropriate combinations. Drug dosages should be optimized. The combinations\nshould be of medicines which are complementary in action. Addition of diuretics in\npatients not responding to a combination of drugs, usually results in good control.\n5. Presence of associated conditions:  Presence of sleep apnea, chronic pain can all impair\ncontrol of BP.\n6. Drug interactions: Some commonly used drugs like non -steroidal anti -inflammatory\ndrugs (NSAIDs), oral contraceptives, corticosteroids and anabolic steroids, and common\ncold remedies which contain sympathomimetics can all result in higher BP. NSAIDs (\nincluding cyclooxygenase -2 inhibitors) can cause salt retention and interfere with the\naction of all antihypertensive s except calcium channel blockers. Addition of a diuretic\nmay mitigate their effect.\n7. Secondary hypertension: The most frequent ca use of secondary hypertension is chronic\nkidney disease, which can be diagnosed on the abnormal urinalysis& blood chemistries,\nat the level of the CHC. The other causes of secondary hypertension would include\nendocrine causes (pheochromocytoma, Cushing\u2019s\u2019 syndrome), vascular causes\n(renovascular hypertension, contraction of aorta , Takayasu\u2019s arteritis); which will\nrequire evaluation by a specialist at a medical college level.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2596, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dd5388ff-a97b-4ae6-bab3-d18cdcf3879e": {"__data__": {"id_": "dd5388ff-a97b-4ae6-bab3-d18cdcf3879e", "embedding": null, "metadata": {"page_label": "23", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0fe0f9ae-393c-4c34-a3c6-7c0b3a8f3111", "node_type": "4", "metadata": {"page_label": "23", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "d1ae213263ca07d39f9306b5477eaaa6bf5a7f05715c3302a6e8a07481dcc840", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 23\n4.8. Therapy of hypertension, comorbidities and associated conditions:\nA large proportion of patients with hypertension have co -morbidities such as diabetes\nmellitus, which need to be managed.\n4.8.1 Diabetes mellitus:\n4.8.1.1 Patients with diabetes mellitus should be initiated on drug treatment when the\nSBP is greater than 140 mm Hg, and the target for control should be a SBP of less than\n140 mm Hg, and a diastolic BP of less than 90 mm Hg.\n4.8.1.2 ACE inhibitors are preferred as initial therapy and calcium channel blockers and\ndiuretics may be used as add on therapy. Thiazide diuretics can be as sociated with\nglucose intolerance.\n4.8.1.3 Drugs which inhibit the renin angiotensin systems - ACE inhibitors and ARBs\nshould be used if the patients have proteinuria (or microalbuminuria).\n4.8.2 Heart disease:\n4.8.2.1Beta-blockers should be prescribed in patients with hypertension and a recent\nmyocardial infarction. These patients should also receive an ACE inhibitor.\n4.8.2.2 In patients with angina, beta -blockers and calcium channel blockers, should be\nconsidered among the antihypertensive drugs for their effect on symptoms.\n4.8.2.3 In patients with heart failure and hypertension, ACE inhibitors, thiazide diuretics,\nand beta -blockers, and mineralocorticoid receptor antagonists are recommended for\nreduction in mortality and hospitalization.\n4.8.3 Kidney disease (diabetic or non-diabetic):\n4.8.3.1 The target for BP reduction should be a SBP of less than 140 mm Hg, but a SBP of\nless than 130 mm Hg should be considered for those with overt proteinuria.\n4.8.3.2. ACE inhibitors /ARBs are effective in reducing albuminuria and   should be used in\npatients with hypertension and overt proteinuria (or microalbuminuria ). Monitoring serum\ncreatinine and potassium in the first week of therapy is advisable after initiation of therapy\nor any increase in the dose of ACE inhibitors.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1938, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04f45ab3-c799-48b6-ad7d-f030a559f167": {"__data__": {"id_": "04f45ab3-c799-48b6-ad7d-f030a559f167", "embedding": null, "metadata": {"page_label": "24", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "38d6a9cb-503d-423e-adc8-a63cf7f5c5a0", "node_type": "4", "metadata": {"page_label": "24", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "fe137e3535831859af6f6ba22fc88c01583f1978788ba758296cd0d7f74f2ef2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 24\n4.8.3.4 Use of ACE inhibitors and Thiazide or thiazide like diuretics should be used as\nother antihypertensive agents, and in the presence of volume overload, loop\ndiuretics like frusemide may be used.\n4.8.4 Cerebrovascular disease:\n4.8.4.1 Prevention of stroke can occur with all classes of antihypertensive drugs if BP is\neffectively controlled.\n4.8.4.2 In patients with a history of stroke or TIA, initiation of drug treatment should be\nconsidered even with Grade 1 hypertension, and a systolic BP of less than 140 mm Hg\nshould be targeted. An ACE inhibitor/ARB is considered an initial drug.\n4.8.4.3 In the first 72 hours of an ischemic stroke, do not administer antihypertensive\ntreatment, since excessive lowering of BP can exacerbate the existing ischemia.\n4.8.4.4 In patients who a re not undergoing thrombolytic therapy for ischemic stroke,\nextreme values of BP, e.g. systolic BP  > 220 mm Hg or diastolic BP > 120 mm Hg should\nbe treated by agents to reduce mean arterial pressure by about 15% in the first hour\nand no more than 25% in the first 24 hours and with gradual reduction thereafter. In\npatients who are candidates for thrombolytic therapy, BP above systolic of 185 mm Hg\nand diastolic of 110 mm Hg should be treated cautiously and maintained below these\nlevels.\n4.8.4.5 In patients with intracerebral haemorrhage, with SBP > 200 mm Hg or MAP 3>150\nmm Hg, aggressive reduction of blood pressure with intravenous infusion of\nantihypertensives is indicated and the patient should be examined every 5 minutes.\n4.8.4.6 In patients with intracerebral haemorrhage , with SBP >180 mm Hg or MAP > 130\nmm Hg, modest reduction of BP to 160/90 is indicated using an intermittent or\ncontinuous IV infusion with frequent re-examination is indicated.\n4.8.4.7 In patients presenting with intracerebral haemorrhage and a SBP o f 150-220 mm\nHg, BP can probably be lowered to a SBP of 140 mm Hg safely.\n4.8.5Hypertension in the elderly:\n4.8.5.1 Postural hypotension is more common in elderly people. Assess patients for postural\nhypotension at diagnosis and on follow up by checking BP in sitting and in standing\nposition after 2 minutes.\n3 MAP = Mean arterial pressure which is calculated as follows MAP = SBP +2(DBP)where SBP is systolic blood\npressure and DBP is diastolic blood pressure                                                    3", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2388, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cd1029ad-3a86-40ad-8447-7cf6b30649a0": {"__data__": {"id_": "cd1029ad-3a86-40ad-8447-7cf6b30649a0", "embedding": null, "metadata": {"page_label": "25", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "13c6c55d-232f-4ac9-bb04-ff25df9de458", "node_type": "4", "metadata": {"page_label": "25", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "59aef84a462759f69d69512f7ba7545f805eec27938f313f701cfed911f7b73e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 25\n4.8.5.2 Postural fall of >20 mm in systolic and >10 mm diastolic indicates postural hypotension\nis a risk factor for falls.\n4.8.5.3 In a patient with postural hypotension titrate target according to standing BP.\n4.8.5.4 Start therapy with lower doses of drugs and change doses or add drugs at a slower rate\nin elderly patients.\n4.8.5.5 In elderly patients less than 80 years of age, the blood pressure target for control may\nbe <140 mm systolic and <90 mm diastolic if the patient is fit and t he treatment is well\ntolerated.\n4.8.5.6 In elderly patients more than 80 years (the very elderly), the blood pressure target for\ncontrol is <150 mm systolic and <90 mm diastolic.\n4.8.5.7 The drug of choice for initiation of therapy in the elderly is a long acting calciu m channel\nblocker, or a low dose thiazide diuretic in the absence of compelling indications.\n4.8.5.8 There is a higher likelihood of certain side effects in the elderly - e.g. hyponatremia in\nthe case of thiazides, and hyperkalemia in the case of ACE inhibitors.\n4.8.5.9 There is a likelihood of drug \u2013drug interactions in the elderly who often receive other\ndrugs; e.g. .NSAIDs for arthritis interferes with action of ACE inhibitors, and diuretics.\n4.9 Hypertensive emergencies:\n4.9.1 Hypertensive emergencies are those in which severe hypertension (elevations of\nsystolic >180 mm Hg) and/ or diastolic (> 120 mm Hg) is associated with symptoms\nand signs of acute ongoing organ damage. Such elevations of blood pressure may\nbe associated with neurologic emergencies (hypertensive encep halopathy, cerebral\ninfarction, and cerebral haemorrhage), cardiac emergencies (acute left ventricular\nfailure, acute coronary syndrome), renal emergencies like acute renal failure, and\nobstetric emergencies like eclampsia (symptoms and signs of such dysfu nction are\nreferred to under the mnemonic of \u2018ABCDEFG\u2019in pathway on assessment and\nmanagement on hypertensive crisis) . Eclampsia can occur even at levels of BP less\nthan 180 mm systolic and/or 120 mm diastolic.\n4.9.2 The magnitude and rate of reduction of BP var ies according to the organ\ninvolvement in the hypertensive emergency. In many hypertensive emergencies\nincluding hypertensive encephalopathy reduction of mean arterial pressure of \u2264 25\npercent in the first hour, with a gradual reduction to 160 mm systolic and diastolic\nof 110 -120 mm Hg over 2 -6 hours, and gradual normalization of blood pressure", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2464, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7ea7f89a-5aaa-415e-bb18-581e9818d578": {"__data__": {"id_": "7ea7f89a-5aaa-415e-bb18-581e9818d578", "embedding": null, "metadata": {"page_label": "26", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e260dda8-0825-4524-b466-877aaa8af6d9", "node_type": "4", "metadata": {"page_label": "26", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "2dc7575ea29ba0c6180f04d11c7bbc876ea7111267759b23fe1842631da2ccf7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 26\nover 24-48 hours is recommended. Parenteral agents like IV labetalol, nicardipine\nmay be used initially with a change to oral agents later.\n4.9.3 In patients with ischemic stroke as noted earlier, reduction of systolic BP below 220\nmm Hg and 120 mm Hg are not treated, unless the patient is being considered for\nthrombolytic therapy.\n4.9.4 Negative recommendation: Oral or sublingual nifedipine may cause excessive,\nabrupt fall of blood pressure which may result in cardiac, cerebral or renal ischemic\ncomplications. It is not recommended in the treatment of any hypertensive\nemergency.\n4.9.5 In the case of acute left ventricular failure reduction of the elevated BP is indicated\nwith a parente ral loop diuretic like frusemide in addition to vasodilators like\nnitroglycerine. In patients with acute coronary syndrome with severe hypertension,\nintravenous nitroglycerine may be used in association with intravenous beta -\nblockers like esmolol or labetalol.\n4.9.6 Patients with a hypertensive emergency should be examined for any clinical clues\nto the presence of secondary hypertension and be evaluated for the same.\n4.10 Hypertensive urgencies:\n4.10.1 This refers to situations when severe hypertension (SBP > 180 mm, DBP> 110 mm) is not\nassociated with any signs of acute or ongoing organ damage (cerebral, cardiac, renal, visual),\nand the patient is relatively asymptomatic except for a mild headache ( none of the symptoms,\nsigns referred to in the mnemonic \u2018ABCDEFG\u2019 in pathway on hypertensive crisis) . Patients with\nsevere hypertension should be assessed clinically and by laboratory investigations, and target\norgan damage should be excluded before hypertensive urgency is diagnosed.\n4.10.2 Hypertensive urgencies may occur in patients with chronic hypertension in a number of\nsituations. This includes non -adherence to therapy, after sudden withdrawal of beta -blocker or\nclonidine therapy, after ingestion of large quantity of salt, or due to anxiety.\n4.10.3 There is no benefit from rapid reduction of BP in patients with severe but asymptomatic\nhypertension and the BP should be reduced over a period of hours and days.\n4.10.4 Nursing the patient in a quiet room and relief of anxiety may reduce BP to a certain\nextent.\n4.10.5 Negative recommendation: Do not attempt excessive, rapid and uncontrolled\nreduction of blood pressure in hypertensive urgencies, with intravenous drugs or oral or", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2447, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8310758c-9655-4a9e-abde-f311bb289f88": {"__data__": {"id_": "8310758c-9655-4a9e-abde-f311bb289f88", "embedding": null, "metadata": {"page_label": "27", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bc792108-53c1-490c-9e75-1b3e066026f7", "node_type": "4", "metadata": {"page_label": "27", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "ee098a7cbd60a4985af9bcb2bb9cfd00da5b016be3e89702dcacdb420ee0b5b3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 27\nsublingual nifedipine . This aggressive reduction of BP in a patient with severe asymptomatic\nhypertension may cause fall of BP below the threshold of autoregulation in vascular beds, and\ncause serious cerebral and cardiac complications related to ischemia.\n4.10.6 Re-institution of therapy or intensification of therapy by increasing the dose of drugs or\nadding a diuretic may suffice for gradual reduction of blood pressure in a patient who\nhas developed severe asymptomatic hypertension on the background of chronic\nhypertension.\n4.10.7 If BP reduction over few hours is required in view of imminent cardiovascular e vents,\nthen oral frusemide, oral clonidine can be used. These can be followed by long term\ntherapy with CCBs, ACE inhibitors or diuretics.\nHypertensive emergencies\nCardiac conditions Acute left ventricular failure\nAcute myocardial infarction\nRenal conditions Acute glomerulonephritis\nRenovascular hypertension\nCerebrovascular conditions Hypertensive encephalopathy\nCerebral infarction\nIntracerebral hemorrhage\nSubarachnoid hemorrhage\nHead injury\nAccelerated hypertension with exudates\nand/or papilledema\nObstetric conditions Eclampsia\nSurgical conditions Postoperative hypertension\nSevere burns\nExcess catecholamines Pheochromocytoma\nAbrupt withdrawal of clonidine, beta-blockers\nTable 14: Conditions presenting as hypertensive emergencies\nDrug Dose Onset of\naction\nAdverse effects Comments\nIV Frusemide 20-40 mg in\n1-2 min\n5-15 min Hypovolemia,\nhypokalemia\nMay be used in\ncombination with\nother dr ugs to\nmaintain their\nefficacy. Indicated in\nacute left ventricular\nfailure", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1637, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "00179ca1-35c4-4a9d-87c9-91878b48232b": {"__data__": {"id_": "00179ca1-35c4-4a9d-87c9-91878b48232b", "embedding": null, "metadata": {"page_label": "28", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "07818704-808e-46b9-a7b0-9762a45a734c", "node_type": "4", "metadata": {"page_label": "28", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "ef26b70ca12fe89a371970d85b8fe6b0644ec3ce6afee038aba2e6d0689057e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 28\nIV labetalol 20-80 mg IV 5-10 min Scalp tingling,\ndizziness, nausea,\nheart block\nCan be used in many\nhypertensive\nemergencies. Avoid in\nacute heart failure\nIV nicardipine 5-15  mg per\nhour as IV\n5-10 min Tachycardia,\nheadache, nausea,\ntachycardia\nCan be used in many\nhypertensive\nemergencies. Avoid in\nacute heart failure\nIV\nnitroglycerine\n5-100 \u00b5g/min 2-5 min Headache, vomiting,\nmethemoglobinemia,\ntolerance\nUseful in myocardial\nischemia with\nhypertension\nTable 15: Selected intravenous drugs useful in management of hypertensive emergencies\n4.11 Integration with other interventions to reduce cardiovascular risks\n4.11.1 The treatment of hypertension should be integrated with treatment of associated\nrisk factors like lipid lowering therapy and antiplatelet therapy, apart from lifestyle\ninterventions already mentioned.\n4.11.2 Antiplatelet therapy with low -dose aspirin (75 mg/day) is recommended in\npatients with controlled hypertension who have previous history of\ncardiovascular event (previous MI, stroke, angina, bypass surgery or coronary\nangioplasty), because of a favourable benefit \u2013harm ratio.\n4.11.3 Low dose aspirin may be considered for those hypertensives who are we ll\ncontrolled and have a high cardiovascular risk (Grade 3 hypertension, 3 or more risk factors,\ntarget organ damage).\n4.11.4 Negative recommendation: Do not use low -dose aspirin in hypertensive patients\nwithout cardiovascular disease and who are at low -moderate risk as the risk of\nmajor bleeds (intracranial and gastrointestinal) outweighs the potential benefit.\n4.11.5 The use of low dose aspirin in patients with diabetes without cardiovascular or\ncerebrovascular disease is not recommended in view of the uncertain risk -benefit\nratio.\n4.11.6 Prescribe statins for use in hypertensive patients with overt atherosclerotic\ncardiovascular disease [ coronary artery disease including acute coronary\nsyndromes, history of myocardial infarction, stable angina), cerebrovascular\ndisease (stroke or transient ischemic attack) , and peripheral arterial disease] ,\nregardless of age.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2110, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "659a65af-a1bd-40b1-a414-c2cf67a5136b": {"__data__": {"id_": "659a65af-a1bd-40b1-a414-c2cf67a5136b", "embedding": null, "metadata": {"page_label": "29", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dfa3f582-94c8-4371-98f1-ef65ac685138", "node_type": "4", "metadata": {"page_label": "29", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "c4ed2a3d57a188190736143818bda3e0d4fde36e3dddc1f06d9dc619017fe91c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 29\n4.11.7 Prescribe statins  in hypertensive patients\n\uf0b7 aged more than 40 years, with LDL \u2013cholesterol more than 190 mg/dl ,\nwhere secondary causes have been ruled out\n\uf0b7 in hypertensive patients  who are diabetic and in the age group of 40 -79\nyears,\n\uf0b7 in hypertensive patients aged more than 40 years with high\ncardiovascular risk (3 or more out of list of 11 cardiovascular risk factors)\n4.11.8 Hypertensive patients who smoke or chew tobacco should be provided advice to\nstop smoking and chewing tobacco.\n5. FOLLOW UP, MONITORING AND IMPROVING ADHERENCE TO THERAPY\nKey Recommendations:\n5.1 A simplified regime using long acting drugs which can be used once a day may improve\nadherence.\n5.2 The patients should be monitored for efficacy of the regimen, both at the clinic and\ncommunity level.  In patients who are yet to achieve target BP, follow -up visits at 1-2 weeks\ncan be scheduled till target BP is achieved. Thereafter the patient can be seen by a physician\nat a frequency determined by the severity of the hypertension, presence of comorbidities,\ntarget organ damage. Streamlined methods to collect drugs should be allowed to enable\ncompliance by the patient.\n5.3. The patients should be monitored for side effects of drugs.\n5.4. The common side effect of calcium channel blockers is peripheral edema, which is dose\ndependent and may subside with reduction of dose or combination with ACE inhibitor.\n5.4.1. The common side effects of diuretics are metabolic side effects like hypokalemia,\nhyperglycemia but which are less frequent when these are used in doses of 12.5 mg and\nwhen they are combined with ACE inhibitors.. A particular concern is of thiazide induced\nhyponatremia which is commoner in the elderly, those with a low body weight. This can\ndevelop rapidly and manifest as altered consciousness, and even seizures, and may\nrequire hospitalisation and administration of normal or hypertonic saline.\n5.4.2. The common side effect of ACE inhibitors is dry cough, which may necessitate\nwithdrawal of therapy. There is a risk of hypotension when ACE inhibitors are started on", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2130, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "130c24ec-093d-47e6-86b0-aeb7c2599c40": {"__data__": {"id_": "130c24ec-093d-47e6-86b0-aeb7c2599c40", "embedding": null, "metadata": {"page_label": "30", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8b5e46e4-6d82-4591-b0d2-02a4cddb69eb", "node_type": "4", "metadata": {"page_label": "30", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "36355c862b30f6eb9c1adcb93596204186eb9d5bd013d2d7508f9ce37073d197", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 30\npatients who are on diuretics, or are on very low salt diet. A small rise in serum\ncreatinine can occur on ACE inhibitors, which is reversible. Hyperkalemia can develop\nwith high doses of ACE inhibitors, but also more commonly in patients with renal\ninsufficiency, diabetes, concurrent use of potassium sparing diuretics, and the elderly.\n5.5. Consider the use of pill counts, participation of a family member in supervision of dr ug\nintake, periodic counselling and provision of patient information leaflets to improve\nadherence and control.\n5.6 Diagnosis and management of hypertension in India, needs to be embedded in the system\nof primary care. A team approach to management of hyperten sion needs to be evolved\nwhich involves the physicians, allied staff and community based health workers.\n5.7 Community based health workers can be trained to play a critical role in meeting the\nchallenge of undetected, untreated and uncontrolled hypertension in India. They can\nimprove detection, promote lifestyle modifications, monitor response and ensure\nadherence to therapy. They can also help prevent hypertension by advising appropriate\nlifestyle modifications in those who have a high normal BP ( 130-139 mm Hg systolic and 85-\n89 mm Hg diastolic)\n5.8 We strongly recommend creation of a hypertension registry at the PHC & CHC level to\nensure tracking of patients and create a system of recall which can involve the community\nbased health workers.\n5.9. Patients with hyper tension should be encouraged to consider home blood pressure\nmonitoring using an automated device which has been validated with a clinic based device.\n5.10. All patients with hypertension, should undergo an annual review of control of BP,\nimplementation of life style modifications (e.g. maintenance of body weight), target organ\ndamage (proteinuria), review of treatment including side effects of drugs.\n5.11 All patients with high normal BP should also be encouraged to undergo an annual review,\nand advised appropr iate lifestyle modifications e.g. dietary changes, weight maintenance, and\nabstinence from tobacco", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2132, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2882bdd5-0512-49fc-a353-7e72b05fe388": {"__data__": {"id_": "2882bdd5-0512-49fc-a353-7e72b05fe388", "embedding": null, "metadata": {"page_label": "31", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "da290cdc-d2ce-468f-a622-6d9c9bb2abd6", "node_type": "4", "metadata": {"page_label": "31", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "836a6dfe3eeab68addb661b5a6f12de911bd34a204b5a8f38d2525837558788b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 31\nANNEXURE 1: PATHWAYS : CLASSIFICATION, ASSESSMENT,\nMANAGEMENT\nPathway 1: Screening Pathway\nReferral to PHC for diagnosis, assessment and management\nRegister in HT registry\n2 sets of BP readings on 2 occasions using validated device and standardised BP\nmeasurement procedure  are > 140 mm systolic and/or >90 mm diastolic (>150/90\nmm in those >80 years)\nAssess Risk Factors -Advice on lifestyle modifications- Urgent referral if BP >180 mm\nsystolic &/or >110 mm diastolic\nScreening by non-physician medical staff or physician\nAny person > 18 years of age seeking\ncare at clinic level\nQuick Reference Guide-Hypertension Page 31\nANNEXURE 1: PATHWAYS : CLASSIFICATION, ASSESSMENT,\nMANAGEMENT\nPathway 1: Screening Pathway\nReferral to PHC for diagnosis, assessment and management\nRegister in HT registry\n Patient referred back to primary care\nteam for follow up and monitoring\n2 sets of BP readings on 2 occasions using validated device and standardised BP\nmeasurement procedure  are > 140 mm systolic and/or >90 mm diastolic (>150/90\nmm in those >80 years)\nAssess Risk Factors -Advice on lifestyle modifications- Urgent referral if BP >180 mm\nsystolic &/or >110 mm diastolic\nScreening by non-physician medical staff or physician\nAny person > 18 years of age seeking\ncare at clinic level\nTargeted screening at community level,\nof age>50 years, obese, smokers, those\nwith any CVD, or  family history of\nhypertension/ premature CVD\nQuick Reference Guide-Hypertension Page 31\nANNEXURE 1: PATHWAYS : CLASSIFICATION, ASSESSMENT,\nMANAGEMENT\nPathway 1: Screening Pathway\nPatient referred back to primary care\nteam for follow up and monitoring\n2 sets of BP readings on 2 occasions using validated device and standardised BP\nmeasurement procedure  are > 140 mm systolic and/or >90 mm diastolic (>150/90\nmm in those >80 years)\nAssess Risk Factors -Advice on lifestyle modifications- Urgent referral if BP >180 mm\nsystolic &/or >110 mm diastolic\nTargeted screening at community level,\nof age>50 years, obese, smokers, those\nwith any CVD, or  family history of\nhypertension/ premature CVD", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2113, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fc5221fa-3b37-4928-b7fb-f75e62c1408f": {"__data__": {"id_": "fc5221fa-3b37-4928-b7fb-f75e62c1408f", "embedding": null, "metadata": {"page_label": "32", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e9792f8b-ef6f-4ba1-8f5f-75a59b3f5cd5", "node_type": "4", "metadata": {"page_label": "32", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "ee2f0c9430399fefaab4a5bd7349ac845d74c9e6e24d44bfe5523137b2acdd20", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 32\nStandard Procedure for BP measurement\n1.Patient\npreparation and\nposition\nPatient should be in a relaxed state for 5 minutes before\nmeasurement of BP. Patient should not have had caffeine in the past\n1 hour or smoked in the past 30 minutes.  Patient should be seated\ncomfortably with back supported, with arm at heart level, and legs in\nan uncrossed position.\n2.Choice of BP\ndevice\nMercury sphygmomanometer or any other device (including\nelectronic digital oscillometric devices) which has been validated\nusing a standard protocol, and has been calibrated regularly.\n3.Cuff size and\nplacement\nThe cuff size should be appropriate for the patient. Length of\nbladder should be 80% of arm circumference and width should be\n40% of arm circumference, and a large adult cuff should be used for\nan obese patient. Patient should not wear any constrictive clothing.\nPlace the midline of the cuff over the pulsations of the brachial\nartery, at a distance of 2-3 cm above the cubital fossa.\n4. Procedure to\nmeasure systolic\nand diastolic blood\npressure( applicabl e\nin case of\nauscultation based\nBP measurement)\nPalpate the radial pulse and then inflate the cuff to 30 mm beyond\nthe disappearance of the radial pulse. Deflate the cuff at 2 -3 mm per\nsecond and record the first and the last sounds as the systolic and\ndiastolic blood pressure respectively.\nIn oscillometric devices the systolic and diastolic BP will be displayed\nautomatically.\nIf the patient is diabetic or above 65 years measure the BP in supine\nand 2 minutes after assuming the standing position to check fo r\npostural hypotension.\n5.No. of\nmeasurements and\nrecording the result\n1.1. At least 2 readings should be taken at an interval of 1\nminute. If the readings differ by more than 5 mm Hg takes a\nthird reading . The lower of the two readings should be\ntaken as the representative SBP and DBP.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1896, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "54560577-da4b-4006-94ff-f2ca49994905": {"__data__": {"id_": "54560577-da4b-4006-94ff-f2ca49994905", "embedding": null, "metadata": {"page_label": "33", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e97110f5-6142-4cf3-992b-a5860d149be2", "node_type": "4", "metadata": {"page_label": "33", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "7d00442df88ee2aca187e57cf4350e167d3124ec96db9ab914ae965fb8e3c5e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 33\nPathway 3: Classification pathway\nPatient with  SBP\u2265 140\nmm  and/or DBP >90 mm\ndocumented by at least 2\nreadings each on 2 visits\nusing a standardised BP\nmeasurement procedure\nGrade 1 HT\nSBP:\u2265 140-159 mm Hg\n&/or\nDBP: \u226590-99 mm Hg\nGrade 2 HT\nSBP: 160-179 mm Hg\n&/or\nDBP: 100-109 mm Hg\nGrade 3 HT\nSBP : \u2265180 mm Hg\n&/or\nDBP:\u2265 >110 mm Hg\nIsolated Systolic hypertension:\nSBP\u2265 \u2265140 mm Hg (if age<80\nyears), \u2265150 mm Hg (ifage >80\nyears) AND DBP < 90 mm Hg\nQuick Reference Guide-Hypertension Page 33\nPathway 3: Classification pathway\nGrade 1 HT\nSBP:\u2265 140-159 mm Hg\n&/or\nDBP: \u226590-99 mm Hg\nGrade 2 HT\nSBP: 160-179 mm Hg\n&/or\nDBP: 100-109 mm Hg\nGrade 3 HT\nSBP : \u2265180 mm Hg\n&/or\nDBP:\u2265 >110 mm Hg\nHypertensive urgency:\nsevere asymptomatic\nhypertension\nHypertensive\nemergency: severe HT\nwith acute cardiac\n/neurologic/renal/retinal\ndysfunction\nIsolated Systolic hypertension:\nSBP\u2265 \u2265140 mm Hg (if age<80\nyears), \u2265150 mm Hg (ifage >80\nyears) AND DBP < 90 mm Hg\nQuick Reference Guide-Hypertension Page 33\nPathway 3: Classification pathway", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1064, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f56b64a7-f527-4296-b880-98756d6531cb": {"__data__": {"id_": "f56b64a7-f527-4296-b880-98756d6531cb", "embedding": null, "metadata": {"page_label": "34", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "97115d27-cb40-40f6-b8d4-b940d1fbb302", "node_type": "4", "metadata": {"page_label": "34", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "66b519364278ee3f698d8f3c55407d2e3b0215530d0a921bb662e37d4bee974f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 34\nPathway 4: Assessment pathway\nPatient with\nhypertension\nGrade 1 HT\nEssential\nevaluation\nHistory for risk factors,\ncardiovascular disease\nExamination for clinical\ncardiovascular disease (angina,\nheart failure, stroke)\nScreening for diabetes, proteinuria\nGrade 2 HT\nDesirable\nevaluation\nHistory and examination as in\nEssential evaluation\nScreening for diabetes + lipids\nUrinalysis,Serum creatinine,ECG\nGrade 3 HT or\npatient <40 years\nand >60 years  or\nResistant HT\nComprehensive\nevaluation\nHistory and examination as in\nEssential evaluation + evidence of\nsecondary HT,Ophthalmoscopy:\nBlood glucose, lipids, serum\ncreatinine, serum sodium and\npotassium,Ultrasound if suspicion\nof renal parenchycmal or\nrenovascular disease,ECHO : in case\nof ? heart failure", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 796, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ce474a38-adf2-48ed-93bc-431d8249093d": {"__data__": {"id_": "ce474a38-adf2-48ed-93bc-431d8249093d", "embedding": null, "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2d58961a-0571-4525-936d-6b48a93435ea", "node_type": "4", "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "2ba28d0511a44c750c98a14682969587a3d3a1cd5cfc989805675ea315541e8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2996b545-c7c8-4dca-afc7-26f32ef4b779", "node_type": "1", "metadata": {}, "hash": "c9b48c7200c73b3320462f9994c29f08a131913e36a8a7267913d18e1e0f7c98", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 35\nPathway 5 A.: Management pathway (algorithm form)\nDrugs are added only if they are required to achieve the target BP of <140/90 mm Hg (in patients <80 years old) or BP <150/90\nmm Hg(in patients >80 years of age)\nAbbreviations: SBP : Systolic blood pressure, DBP: Diastolic blood pressure, TOD :target organ damage, DM: diabetes mellitus,\nCAD: coronary artery disease,CHF: Congestive heart failure, CKD: Chronic kidney disease. Drug abbreviations: A : Angiotensin\nconverting enzyme(ACE) inhibitors (e.g. enalapril) or Angiotensin II receptor blockers(ARBs)(e.g. losartan) only if intolerance to\nACE inhibitors, C: Calcium channel blocker(e.g. amlodipine), D: Thiazide diuretics(e.g. hydrochorothiazide), B: Beta-blockers(e.g.\natenolol), MRA : Mineralocorticoid receptor antagonist (e.g. spironolactone).\nFootnotes :!  Other Risk factors(apart from hypertension) : age ( > 55 years in men, 65 years in women), male gender,  diabetes\nmellitus,smoking,obesity(including abdominal obesity), dyslipidemia, impaired glucose tolerance, famil y history of premature\ncoronary artery disease.\n* calcium channel bloc kers are antihypertensives of choice in the elderly (> 60 years).# Patients with CAD and history of\nmyocardial infarction should receive both beta-blockers and ACE inhibitors.\u00a7 Patients with CKD may require loop diuretics if the\nGlomerular filtration rate is low. Those patients who are started on ACE inhibitorswill require monitoring of serum creatinine\nand potassium after initiation of treatment.Based on references(24, 49)\nBlood pressure \u2265 140/90 mm Hg,in adults aged 18-79 years,on multiple occasions\nusing standardized procedure (for age > 80 years blood pressure >150/90 )\nLifestyle modifications (Dietary change-salt restriction,low fat diet, reduce weight, Stop smoking) in all\npatients. Trial of lifestyle modifications in uncomplicated  Grade 1 HT for 3 months  before initiation of\ndrug therapy.\nPatients without compelling\nindications\n(Hypertension alone )\nGrade 3 HT (SBP \u2265180,\nDBP \u2265 110)\nGrade 1 HT(SBP 140-159, DBP 90-99)\nGrade 2 HT (SBP 160-179, DBP 100-\n109)\nStart with One drug\nA or C* or D\nUSE TWO DRUGS (preferred strategy)\nA+ C  OR  C+ D OR   A+ D\nUSE 3 drugs\nA+C +D\nNO response to 3 drugs - Resistant HT-\nConsider Specialist referral\nIncrease A or C or D to\nmaximal dose (less\npreferred strategy)\nGrade 1 hypertension with TOD/DM/associated clinical\nconditions or > 3 risk factors\n!\nQuick Reference Guide-Hypertension Page 35\nPathway 5 A.: Management pathway (algorithm form)\nDrugs are added only if they are required to achieve the target BP of <140/90 mm Hg (in patients <80 years old) or BP <150/90\nmm Hg(in patients >80 years of age)\nAbbreviations: SBP : Systolic blood pressure, DBP: Diastolic blood pressure, TOD :target organ damage, DM: diabetes mellitus,\nCAD: coronary artery disease,CHF: Congestive heart failure, CKD: Chronic kidney disease. Drug abbreviations: A : Angiotensin\nconverting enzyme(ACE) inhibitors (e.g. enalapril) or Angiotensin II receptor blockers(ARBs)(e.g. losartan) only if intolerance to\nACE inhibitors, C: Calcium channel blocker(e.g. amlodipine), D: Thiazide diuretics(e.g. hydrochorothiazide), B: Beta-blockers(e.g.\natenolol), MRA : Mineralocorticoid receptor antagonist (e.g. spironolactone).\nFootnotes :!  Other Risk factors(apart from hypertension) : age ( > 55 years in men, 65 years in women), male gender,  diabetes\nmellitus,smoking,obesity(including abdominal obesity), dyslipidemia, impaired glucose tolerance, famil y history of premature\ncoronary artery disease.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3579, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2996b545-c7c8-4dca-afc7-26f32ef4b779": {"__data__": {"id_": "2996b545-c7c8-4dca-afc7-26f32ef4b779", "embedding": null, "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2d58961a-0571-4525-936d-6b48a93435ea", "node_type": "4", "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "2ba28d0511a44c750c98a14682969587a3d3a1cd5cfc989805675ea315541e8f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce474a38-adf2-48ed-93bc-431d8249093d", "node_type": "1", "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "de7e9d367c93819e9179569ac53506c8190b2c2797cb423b063651560b5a5542", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2b62843-6dcb-4268-a8c7-9bcc036e1fd8", "node_type": "1", "metadata": {}, "hash": "3bd28d103e17c9ee3e905274719815a7dbab1c3ec07834aa37ab273c62d17a3f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Drug abbreviations: A : Angiotensin\nconverting enzyme(ACE) inhibitors (e.g. enalapril) or Angiotensin II receptor blockers(ARBs)(e.g. losartan) only if intolerance to\nACE inhibitors, C: Calcium channel blocker(e.g. amlodipine), D: Thiazide diuretics(e.g. hydrochorothiazide), B: Beta-blockers(e.g.\natenolol), MRA : Mineralocorticoid receptor antagonist (e.g. spironolactone).\nFootnotes :!  Other Risk factors(apart from hypertension) : age ( > 55 years in men, 65 years in women), male gender,  diabetes\nmellitus,smoking,obesity(including abdominal obesity), dyslipidemia, impaired glucose tolerance, famil y history of premature\ncoronary artery disease.\n* calcium channel bloc kers are antihypertensives of choice in the elderly (> 60 years).# Patients with CAD and history of\nmyocardial infarction should receive both beta-blockers and ACE inhibitors.\u00a7 Patients with CKD may require loop diuretics if the\nGlomerular filtration rate is low. Those patients who are started on ACE inhibitorswill require monitoring of serum creatinine\nand potassium after initiation of treatment.Based on references(24, 49)\nBlood pressure \u2265 140/90 mm Hg,in adults aged 18-79 years,on multiple occasions\nusing standardized procedure (for age > 80 years blood pressure >150/90 )\nLifestyle modifications (Dietary change-salt restriction,low fat diet, reduce weight, Stop smoking) in all\npatients. Trial of lifestyle modifications in uncomplicated  Grade 1 HT for 3 months  before initiation of\ndrug therapy.\nStart Drug therapy\nPatients without compelling\nindications\n(Hypertension alone )\nGrade 3 HT (SBP \u2265180,\nDBP \u2265 110)\nUSE TWO DRUGS (preferred strategy)\nA+ C  OR  C+ D OR   A+ D\nNO response to 3 drugs - Resistant HT-\nConsider Specialist referral\nPatients with compelling indications\n(Hypertension with associated clinical\nconditions)\nDM: A /C, D\nCAD: B + A\n#\n, C\nCHF: D+ A+ B, MRA\nCKD: A, C, D\n\u00a7\nGrade 1 hypertension with TOD/DM/associated clinical\nconditions or > 3 risk factors\n!\n Grade 2 HT and Grade 3 HT\nQuick Reference Guide-Hypertension Page 35\nPathway 5 A.: Management pathway (algorithm form)\nDrugs are added only if they are required to achieve the target BP of <140/90 mm Hg (in patients <80 years old) or BP <150/90\nmm Hg(in patients >80 years of age)\nAbbreviations: SBP : Systolic blood pressure, DBP: Diastolic blood pressure, TOD :target organ damage, DM: diabetes mellitus,\nCAD: coronary artery disease,CHF: Congestive heart failure, CKD: Chronic kidney disease. Drug abbreviations: A : Angiotensin\nconverting enzyme(ACE) inhibitors (e.g. enalapril) or Angiotensin II receptor blockers(ARBs)(e.g. losartan) only if intolerance to\nACE inhibitors, C: Calcium channel blocker(e.g. amlodipine), D: Thiazide diuretics(e.g. hydrochorothiazide), B: Beta-blockers(e.g.\natenolol), MRA : Mineralocorticoid receptor antagonist (e.g. spironolactone).\nFootnotes :!  Other Risk factors(apart from hypertension) : age ( > 55 years in men, 65 years in women), male gender,  diabetes\nmellitus,smoking,obesity(including abdominal obesity), dyslipidemia, impaired glucose tolerance, famil y history of premature\ncoronary artery disease.\n* calcium channel bloc kers are antihypertensives of choice in the elderly (> 60 years).# Patients with CAD and history of\nmyocardial infarction should receive both beta-blockers and ACE inhibitors.\u00a7 Patients with CKD may require loop diuretics if the\nGlomerular filtration rate is low. Those patients who are started on ACE inhibitorswill require monitoring of serum creatinine\nand potassium after initiation of treatment.Based on references(24, 49)\nLifestyle modifications (Dietary change-salt restriction,low fat diet, reduce weight, Stop smoking) in all\npatients.", "mimetype": "text/plain", "start_char_idx": 2925, "end_char_idx": 6609, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c2b62843-6dcb-4268-a8c7-9bcc036e1fd8": {"__data__": {"id_": "c2b62843-6dcb-4268-a8c7-9bcc036e1fd8", "embedding": null, "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2d58961a-0571-4525-936d-6b48a93435ea", "node_type": "4", "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "2ba28d0511a44c750c98a14682969587a3d3a1cd5cfc989805675ea315541e8f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2996b545-c7c8-4dca-afc7-26f32ef4b779", "node_type": "1", "metadata": {"page_label": "35", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "6d2961fd6703fca83e828b3ef45fd65d0bf1c42961052f359cc69b73d375ffaa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Footnotes :!  Other Risk factors(apart from hypertension) : age ( > 55 years in men, 65 years in women), male gender,  diabetes\nmellitus,smoking,obesity(including abdominal obesity), dyslipidemia, impaired glucose tolerance, famil y history of premature\ncoronary artery disease.\n* calcium channel bloc kers are antihypertensives of choice in the elderly (> 60 years).# Patients with CAD and history of\nmyocardial infarction should receive both beta-blockers and ACE inhibitors.\u00a7 Patients with CKD may require loop diuretics if the\nGlomerular filtration rate is low. Those patients who are started on ACE inhibitorswill require monitoring of serum creatinine\nand potassium after initiation of treatment.Based on references(24, 49)\nLifestyle modifications (Dietary change-salt restriction,low fat diet, reduce weight, Stop smoking) in all\npatients. Trial of lifestyle modifications in uncomplicated  Grade 1 HT for 3 months  before initiation of\ndrug therapy.\nCHF: D+ A+ B, MRA\nGrade 2 HT and Grade 3 HT", "mimetype": "text/plain", "start_char_idx": 5763, "end_char_idx": 6764, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "856106da-ca0b-4ffc-a3ed-994c6b11616b": {"__data__": {"id_": "856106da-ca0b-4ffc-a3ed-994c6b11616b", "embedding": null, "metadata": {"page_label": "36", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4a4cf3bc-1f30-41d6-ad0e-3c4d2766941e", "node_type": "4", "metadata": {"page_label": "36", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "e5bb19e365ca80af13dae632a28708f74d3e06fee8c1a8f53fb59ba819676cb2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 36\nPathway 6:Patient flow pathway\nnon physician health staff-\nscreen-refer for diagnosis-educate-\nassess-advise on lifestyle &adherence-\nmonitor-follow up\nPhysician at PHC/CHC\ndiagnose-classify-educate-assess (TOD,\nassociated clinical conditions), advise-\nregister -initiate therapy- refer if\nindicated, follow up\nQuick Reference Guide-Hypertension Page 36\nPathway 6:Patient flow pathway\nnon physician health staff-\nscreen-refer for diagnosis-educate-\nassess-advise on lifestyle &adherence-\nmonitor-follow up\nPhysician at PHC/CHC\ndiagnose-classify-educate-assess (TOD,\nassociated clinical conditions), advise-\nregister -initiate therapy- refer if\nindicated, follow up\nReferrals to District\n1. In case of hypertensive emergency after\ninitiation of treatment\n2. For evaluation of resistant hypertension.\n3. For management of certain associated\nclinical conditions -Ischemic heart disease\nQuick Reference Guide-Hypertension Page 36\nPathway 6:Patient flow pathway", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 999, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "323820fb-677b-47f9-b987-dba191801d42": {"__data__": {"id_": "323820fb-677b-47f9-b987-dba191801d42", "embedding": null, "metadata": {"page_label": "37", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b5952c43-41a2-47d7-b2ca-c1737bdaeb93", "node_type": "4", "metadata": {"page_label": "37", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "be58d46cba50e11e31a5d165f498738dcc2e38c65d0d845256fe08b9b0e118e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b95b6c8-8e95-426d-a86a-d0b5388153b7", "node_type": "1", "metadata": {}, "hash": "ffb5394b10be96f2a8253f8fd691ce7a15094af919463f49f1e22e242995a348", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 37\nPathway 7: Assessment and management pathway in a patient with\nhypertensive crisis (> 180 mm systolic, >110-120 mm diastolic)\n*Also investigate as appropriate: Serum creatinine (in all), X-ray chest, ECG, CT scan if indicated.\nCardiac emergencies: Acute l eft ventricular failure, Myocardial infarction, unstable angina; Neurologic\nemergencies: Hypertensive encephalopathy, Ischemic stroke, Intracerebral haemorrhage, subarachnoid\nhaemorrhage, Head injury ;Renal emergencies: Acute glomerulonephritis #, renovascular hypertension;\nSurgical emergencies: Post-operative hypertension, severe burns ;Obstetric: Eclampsia#\n#: Hypertensive emergency may occur even at BP levels lower than 180 mm systolic and 110 mm\ndiastolic\nAssess for following*\nA: Altered consciousness\nB: Breathlessness\nC: Chest Pain (ischemic)\nD: Deficit (weakness in one or more limbs) or Decreased urinary output\nE: Edema\nF: Fundus if feasible- hemorrhages, exudates, papilledema\nG: Generalised seizures\nAsymptomatic :\nNo A/B/C/D/E/F/G\nHYPERTENSIVE\nURGENCY\nReduce BP over hours\nto days.\nUse  oral drugs\nDO NOT USE\nSUBLINGUAL\nNIFEDIPINE\nQuick Reference Guide-Hypertension Page 37\nPathway 7: Assessment and management pathway in a patient with\nhypertensive crisis (> 180 mm systolic, >110-120 mm diastolic)\n*Also investigate as appropriate: Serum creatinine (in all), X-ray chest, ECG, CT scan if indicated.\nCardiac emergencies: Acute l eft ventricular failure, Myocardial infarction, unstable angina; Neurologic\nemergencies: Hypertensive encephalopathy, Ischemic stroke, Intracerebral haemorrhage, subarachnoid\nhaemorrhage, Head injury ;Renal emergencies: Acute glomerulonephritis #, renovascular hypertension;\nSurgical emergencies: Post-operative hypertension, severe burns ;Obstetric: Eclampsia#\n#: Hypertensive emergency may occur even at BP levels lower than 180 mm systolic and 110 mm\ndiastolic\nSBP>180\nDBP>110-120\nAssess for following*\nA: Altered consciousness\nB: Breathlessness\nC: Chest Pain (ischemic)\nD: Deficit (weakness in one or more limbs) or Decreased urinary output\nE: Edema\nF: Fundus if feasible- hemorrhages, exudates, papilledema\nG: Generalised seizures\nAsymptomatic :\nNo A/B/C/D/E/F/G\nHYPERTENSIVE\nURGENCY\nReduce BP over hours\nto days.\nUse  oral drugs\nDO NOT USE\nSUBLINGUAL\nNIFEDIPINE\nOne or more of symptoms\n/signs in  A-G\nHYPERTENSIVE\nEMERGENCY\nReduce BP (only rarely to normal)\nover minutes to hours -according\nto type of emergency\nUse parenteral drugs : choice\ndepends upon type of emergency\nDO NOT USE SUBLINGUAL\nNIFEDIPINE\nObstetric\nSurgical\nCardiac\nemergencie\ns\nNeurologic\nemergencies\nRenal\nemergenci\nes\nAccelerated\nMalignant\nHypertension\nQuick Reference Guide-Hypertension Page 37\nPathway 7: Assessment and management pathway in a patient with\nhypertensive crisis (> 180 mm systolic, >110-120 mm diastolic)\n*Also investigate as appropriate: Serum creatinine (in all), X-ray chest, ECG, CT scan if indicated.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2944, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8b95b6c8-8e95-426d-a86a-d0b5388153b7": {"__data__": {"id_": "8b95b6c8-8e95-426d-a86a-d0b5388153b7", "embedding": null, "metadata": {"page_label": "37", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b5952c43-41a2-47d7-b2ca-c1737bdaeb93", "node_type": "4", "metadata": {"page_label": "37", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "be58d46cba50e11e31a5d165f498738dcc2e38c65d0d845256fe08b9b0e118e2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "323820fb-677b-47f9-b987-dba191801d42", "node_type": "1", "metadata": {"page_label": "37", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "6cfcbe30e1caf3775e8084125c805a91534f1afedd9a5377867f0d3ff3a4946a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cardiac emergencies: Acute l eft ventricular failure, Myocardial infarction, unstable angina; Neurologic\nemergencies: Hypertensive encephalopathy, Ischemic stroke, Intracerebral haemorrhage, subarachnoid\nhaemorrhage, Head injury ;Renal emergencies: Acute glomerulonephritis #, renovascular hypertension;\nSurgical emergencies: Post-operative hypertension, severe burns ;Obstetric: Eclampsia#\n#: Hypertensive emergency may occur even at BP levels lower than 180 mm systolic and 110 mm\ndiastolic\nReduce BP (only rarely to normal)\nover minutes to hours -according\nto type of emergency\nUse parenteral drugs : choice\ndepends upon type of emergency\nDO NOT USE SUBLINGUAL\nNIFEDIPINE", "mimetype": "text/plain", "start_char_idx": 2945, "end_char_idx": 3619, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cbf83524-0535-4353-90b3-a07e2615dd44": {"__data__": {"id_": "cbf83524-0535-4353-90b3-a07e2615dd44", "embedding": null, "metadata": {"page_label": "38", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bea62208-6772-4058-9f03-3da59893bc45", "node_type": "4", "metadata": {"page_label": "38", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "29b2a5a37d0399ec95940dc4e918b16c2c60f3cf17d11baa3da3bc2a1f85d148", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 38\nANNEXURE 2: LIFE STYLE CHANGES RECOMMENDED FOR PATIENTS\nDIAGNOSED TO HAVE HYPERTENSION AND FOR THOSE AT RISK OF\nDEVELOPING HYPERTENSION\nBackground:\nLifestyle modifications are an integral part of the management of persons with hypertension,\nregardless of severity of hypertension. Reduction of BP following lifestyle modifications may\nsuffice for the control of grade I hypertension, while they may aid the control of hypertension\nand reduce the dosages of drugs required for control of other grades of hypertension. Lifestyle\nmodifications also help to reduce the overall cardiovascular risk in a person with hypertension.\nLifestyle modifications are also an integral part of the prevention of hypertension at both an\nindividual and the population level, and may help prevent progression of high normal BP to\nhypertensive levels.\n1. Physical Activity (adapted from ref. (84))\n\uf0b7 Physical activity includes daily activity like walking and cycling, household work,\nwork related activity, and leisure activity. Moderate intensity physical activity of 30\nminutes per day or at least 2.5 hours (150 mins) per week, which can be perf ormed\nin bouts of 10 minutes or more in 4 -7 sessions per week, should be advised to all\nindividuals for its cardio -protective effect . Moderate intensity physical activity\nincludes any activity which can increase the heart rate, make the breathing rapid\nand make the body warmer such as brisk walking (at 3 -4 mph), stair -climbing, light\nswimming, walking the treadmill at 3-4 mph, or . 45 minutes (accumulated) exercise\nper day is recommended for cardiovascular fitness, while 60 minutes (accumulated)\nper day is recommended for weight reduction.  The specific form of physical activity\nchosen by or for the patient should be enjoyable and sustainable.\n\uf0a7 Alternatively persons can indulge in 75 minutes of vigorous physical activity like\nrunning (at 6-8 mph), cycling at 12-14 mph. This kind of activity makes the breathing", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1998, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1164f7a9-b54f-43bb-9e38-7806f52e2586": {"__data__": {"id_": "1164f7a9-b54f-43bb-9e38-7806f52e2586", "embedding": null, "metadata": {"page_label": "39", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "240bcf4f-e2d4-493a-b8cc-2d31d6dfa3f3", "node_type": "4", "metadata": {"page_label": "39", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "dea86043d41689fa98c53b785aa97fbc2e3582b89ae694882f182dfdb5a1e85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 39\nvery hard, the heartbeat rapid and makes it difficult to carry on a conversation\ncomfortably.\n\uf0a7 All adults should include physical activities to improve muscle strength at least twice\na week.\n\uf0a7 Regular aerobic exercises can reduce the systolic blood pressure average of 4 mmHg\nand diastolic BP by an average of 2.5 mmHg.(29)\n\uf0a7 Epidemiologic evidence suggests that physical activity reduces cardiovascular\nmorbidity and mortality.  There is strong evidence that regular physical activity has\nan independent cardio protective effect. Physical activity improves cardiorespiratory\nfitness, lowers SBP and DBP, improves insulin sensitivity and glycemic control, helps\nreduce and control weight, and lowers markers of inflammation.(53)\n\uf0a7 Chronically sedentary individuals should not start a program of vigorous activity\nsuddenly, but should gradually increase the dura tion and intensity of physical\nactivity, starting for example with 10 minutes of moderate activity per session . (85)\nThis is done to minim ise the risk of a sudden cardiac event and musculoskeletal\ninjuries. Any patient experiencing chest discomfort, jaw pain, palpitations, syncope\nor dyspnea, should undergo evaluation before continuing with exercise. Patients\nwith decompensated heart failure and acute coronary syndromes should not\nembark on an exercise program.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1373, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a8575b05-e9a3-4a71-a478-44c2d07edf0b": {"__data__": {"id_": "a8575b05-e9a3-4a71-a478-44c2d07edf0b", "embedding": null, "metadata": {"page_label": "40", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a12f41e7-5b11-4a47-a46b-bda98ecc4fb7", "node_type": "4", "metadata": {"page_label": "40", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "f14d3809b6013c0bc2a88a905b5626bc9cf71dfd26ff38f3915dfa8330afe0d1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 40\nSource: Ref: (85)\nSource : ref(85)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 77, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "835c77f8-1e01-4680-a939-1cc3b682440e": {"__data__": {"id_": "835c77f8-1e01-4680-a939-1cc3b682440e", "embedding": null, "metadata": {"page_label": "41", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f17fec79-7d92-4e31-b263-4b546d50c619", "node_type": "4", "metadata": {"page_label": "41", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "fb498e0979881400eb62650cd64246654f4f1b0e198e70c626d2d5bf4346e796", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 41\n2. Weight Reduction: achieve and maintain desirable body weight.\nAll individuals who are overweight or obese should be encouraged to lose weight through a\ncombination of a reduced calorie di et, increased physical activity and behaviour\nmodification. Dietary changes and recommendations for physical activity are mentioned in\nother sections.\nOverweight or obesity is assessed by measuring body mass index (BMI), which is calculated\nas weight in kg/height in meter 2. For Indian population 18.5 to 22.9 BMI is normal, 23 to\n24.9 is considered as overweight and BMI of \u226525 kg/m2 is considered as obesity in Indians.4\nApart from BMI which is a measure of general adiposit y, it is also important to measure the\nabdominal adiposity, which is also associated with a higher cardiovascular risk. Abdominal\nadiposity can be measured by measurement of the waist circumference and the waist -hip\nratio. The waist circumference is measur ed at the end of several consecutive natural\nbreaths, midpoint between the top of the iliac crest and the lower margin of the last\npalpable rib in the mid axillary line. Waist circumference should be <90 cm for men and <80\ncm for women. Another measure of central obesity is Waist Hip Ratio (WHR), which is the\nwaist circumference divided by the hip circumference. The hip circumference is measured\nat the maximum circumference of the buttocks.  Normal WHR is <0.85 for women and <0.90\nfor men.\n4Misra A, Chowbey P, Makkar B, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the\nmetabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical\nmanagement. JAPI. 2009;57(2):163-170.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1713, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "495c3018-429f-4539-ba44-47ae5301449e": {"__data__": {"id_": "495c3018-429f-4539-ba44-47ae5301449e", "embedding": null, "metadata": {"page_label": "42", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2a55a4fe-af83-46b2-8140-86f11a7707ff", "node_type": "4", "metadata": {"page_label": "42", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "0e34e9926235c4437eb3e02daf5f6fac9800c5303ed1966e6fd8a4af73815a32", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 42\n3. Alcohol Consumption\n\uf0a7 Reducing alcohol intake can lower the blood pressure substantially. On other hand\nmoderate drinking and binge drinking increases the blood pressure and risk of\ndeveloping hypertension.\n\uf0a7 Zero alcohol consumption is recommended for women who are pregnant or\nplanning to have pregnancy and also for those hypertensives who had already\nsuffering from a complication due to hypertension like stroke, heart disease or renal\ndisease.\n\uf0a7 Alcohol consumption is measured in terms of units of alcohol (UK) or standard drinks\n(e.g. Australia, USA). 1 unit of alcohol is 10 ml ethanol (around 8 gms ethanol), while\n1 standard drink contains 10 g ethanol (Australia) or 14 g ethanol (USA).\n\uf0a7 The no. of units consumed per day can be calculated using the drink volume and the\nAlcohol by (ABV), which is mentioned as a percentage on the container.  E.g. Beer\nmay be around 5% ABV, wine is around 12.5%, while whisky and vodka are around\n40% ABV.\n\uf0a7 The number of units of alcohol = Drink volume x ABV /1000. Therefore 100 ml of\nwhisky will be 100 x 40/1000= 4 units.\n\uf0a7 Healthy adults should not regularly drink more than 3 -4 units per day in the case of\nmen and 2 -3 units in the case of women. If there has been heavy alcohol\nconsumption, there should be no alcohol intake for 48 hours.\n\uf0a7 Tips on cutting down should be offered to patients and should be employed in an\nincremental fashion (86) : These include keeping track of alcohol intake ( including\ncounting and measuring) and keeping intake within recommended limits, setting\ngoals for consumption, drinking slowly and preferably with some food in the\nstomach. In patients who have decided to quit, avoiding triggers, dealing with urges,\nand refusing offers of drinks politely are of vital importance. Talking and enlisting the\nsupport of spouses, non -drinking friends, and mutual support groups like alcoholics\nanonymous are also very helpful.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1955, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "24a0081b-bb10-439c-93e5-d8d9c7999762": {"__data__": {"id_": "24a0081b-bb10-439c-93e5-d8d9c7999762", "embedding": null, "metadata": {"page_label": "43", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2a2fb3b0-7524-4546-b2bb-3f5ea854c3ba", "node_type": "4", "metadata": {"page_label": "43", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "6b0712c9ebb4a6ad0fd3c35b07b39aa5820e70215dc06ff75481cfa63f6ced43", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 43\n4. Tobacco cessation\nNon-smokers should be encouraged not to start smoking.(87)All smokers should be encouraged\nto quit smoking, and should be supported by the health professional in their efforts to do so.(87)\nPatients who use other forms of tobacco should be motivated to stop doing so.\n\uf0a7 Smoking cessation may not reduce the blood pressur e directly but markedly reduces\noverall cardiovascular risk. The risk of myocardial infarction is 2 \u20136 times higher and\nthe risk of stroke is 3 times higher in people who smoke than in non -smokers.\nSmokers who quit reduce their risk of coronary heart disease.\n\uf0a7 Brief advice from health professionals is effective in helping persons to quit smoking,\nincreasing quit rates. Even 3 \u20135 minutes taken to encourage smokers to attempt to\nquit can increase success rates.\n\uf0a7 The WHO has recommended a 5 As approach to aid in smoking cessation in routine\npractice- The patient should be asked about smoking status at every opportun ity.\nThen the patient should be advised about to quit smoking, and assessed about his\ndegree of addiction and readiness to quit. T he health professional should assist in\nformulating a smoking cessation strategy including setting a quit date, counseling\nand other measures, and finally arrange a follow up visit.\n\uf0a7 Pharmacotherapy to stop smoking with nicotine replacement therapy, bupropi on,\nnortryptiline and varenicline are effective and should be offered to motivated\nsmokers who fail to quit with counseling. The risk of adverse effects is small and is\ngenerally outweighed by the significant risk of continuing to smoke.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1636, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dc3f7922-8748-439d-bd7b-dc35f44a8247": {"__data__": {"id_": "dc3f7922-8748-439d-bd7b-dc35f44a8247", "embedding": null, "metadata": {"page_label": "44", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7cbdc3c1-5fea-482b-9014-7b4436534817", "node_type": "4", "metadata": {"page_label": "44", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "6b19d31ba2ec463f0fda05ee27f9d70c93affdeb1d73334430cb380c509b4604", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 44\nRef: (23)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 52, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ef140abc-84bb-45c5-9869-226fcbe92386": {"__data__": {"id_": "ef140abc-84bb-45c5-9869-226fcbe92386", "embedding": null, "metadata": {"page_label": "45", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b365dfd4-fc81-4eba-b7c5-aceec8307475", "node_type": "4", "metadata": {"page_label": "45", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "cac14335aa648e0897cde66713bbc2a9de06cf34b3c506f6f454dd4b155435a9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 45\n5. Dietary Recommendations\nAll patients should be encouraged to adopt a heart healthy diet.\nFat: All individuals should be strongly encouraged to reduce total fat and saturated fat\nintake. Total fat intake should be reduced to about 30% of calories,  saturated fat to less\nthan 10% of calories, trans -fatty acids ( present in margarine and bakery products )intake\nshould be reduced as much as possible or eliminated and most dietary fat should be\npolyunsaturated (up to 1 0% of calories) or monounsaturated (10 \u201315% of calories).\nSalt: All individuals should be strongly encouraged to reduce daily salt intake by at least one\nthird a nd, if possible, to <5g or <90 mmol per day.\nFruits, vegetables, fibre: All individuals should be encouraged to eat at least 400 g a day of a\nrange of fruits and vegetables as well as whole grains and pulses.\n6. Salt Intake\nAll patients should be strongly encouraged to limit their salt intake to < 5 g salt(or 90 mmol)\nper day as per WHO recommendations. (87) There is lack of representative data on salt intake\nin India, although in a study in urban India, the mean intake was found to be 8.5 g salt per\nday.(88)\nReduction of salt intake can be accomplished by not adding additional salt in diet, choosing\nfoods processed without salt, avoiding high -salt pro cessed foods, salty snacks, takeaway\nfoods high in salt and salt added during cooking or at the table.\nPreparations which are high in salt and need to be moderated are: Pickles, chutneys, sauces\nand ketchups, papads, chips and salted biscuits, cheese and salted butter, bakery products\nand dried salted fish.\nThe above recommendation for dietary salt restriction may have to be individualisedin the\ncase of certain occupational exposures. Acclimation to heat occurs rapidly; thus, within a few\ndays of exposure to hot and humid conditions, individuals lose only small amounts of sodium\nthrough sweat. But in the case of workers performing intense physical activity under\nconditions of heat stress, may lose significant amounts of fluid and salt  in sweat. In a study it", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2109, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "696d2370-e7ed-4b0f-ba9c-5b3ca5aaa83f": {"__data__": {"id_": "696d2370-e7ed-4b0f-ba9c-5b3ca5aaa83f", "embedding": null, "metadata": {"page_label": "46", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dcc545cf-a6f2-4c1d-a78c-6d5d457731ef", "node_type": "4", "metadata": {"page_label": "46", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "8f5adfd53421c380b88c2d23c3320bf1c3dbf1f63f6689136e4b4656d4f225e0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 46\nwas estimated that a 10 hour shift of working in moderately hot climatic conditions(35 0C) can\nresult in loss of 10-15 g salt.(89)\n7. Stress management\n\uf0a7 In hypertensive patients in whom stress may be contributing to blood pressure\nelevation, stress management should be considered as an intervention.\n\uf0a7 A recent systematic review and meta -analysis of Yoga concluded that there were\nclinically important effects on cardiovascular disease risk factors and that Yoga could\nbe considered an ancillary intervention to reduce cardiovascular risk. (90)With regard\nto its role in hypertension management, another systematic review concluded that\nthere was emerging but low -quality evidence for Yoga as an adjunct to medical\ntherapy, but larger confirmatory studies were required. (91)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 822, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ba81e23b-40c2-4fe4-b4b2-71f60798df24": {"__data__": {"id_": "ba81e23b-40c2-4fe4-b4b2-71f60798df24", "embedding": null, "metadata": {"page_label": "47", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dfe261a9-4249-4fb1-a2cc-c4391a005447", "node_type": "4", "metadata": {"page_label": "47", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "cc8057477334d6ca1b9a01ca1b3e32bf09210fd263f6a25c48dcc09030851477", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 47\nANNEXURE 3: FORMULARY\nCalcium channel blockers (CCBs) with focus on amlodipine\nPharmacology of CCBs : These drugs interfere with the inward movement of calcium ions\nthrough the slow channels of cell membranes in the heart and the vascular smooth muscle.\nThey are divided into 2 major classes , the dihydropyridines CCBs which includes\namlodipine,nifedipine, felodipine) which do not have a major negative inotropic effect and no\nantiarrhythmic activity,  and the non-dihydropyridines like verapamil, and diltiazem, which have\nboth significant negative inotropic and anti-arrhythmic activity.\nAmlodipine: Amlodipine has a very long elimination half - life (35 to 48 hours) and can be given\nonce daily.  It has a good safety profile, very few drug interactions, and no adverse effect on\nglucose, lipid levels. Other agents in this class like cilnidipine, nicardipine, lerc anidipine, have no\nmajor advantage over amlodipine whose outcome benefits have been established in large\ntrials. An isomer of amlodipine, S -Amlodipine is also marketed in India, along with the\namlodipine in its racemic form. The limited high quality data a vailable  suggests that there is no\ndifference in therapeutic efficacy as well as adverse effects between the two forms (92). The S-\nAmlodipine form is more expensive. The racemic amlodipine is available in various forms \u2013\namlodipine besilate, amlodipine mes ilate, and amlodipine maleate, but these are\ninterchangeable.\nIndications for amlodipine:\nUsed alone or in combination for hypertension, chronic stable angina, coronary artery disease\nwithout heart failure or an ejection fraction <40%\nDose, titration, and use in combinations\nInitial dose: 5 mg once daily. In elderly, small patients, and patients with hepatic impairment,\nthe initial dose may be 2.5 mg once daily. The dose of 2.5 mg may also be used when adding\namlodipine to other antihypertensive agents. Dose may be increased at intervals of 7-14 days to\nachieve BP goals. Doses may be increased up to a maximum of 10 mg once daily.\nAmlodipine can be used in combination with ACE inhibitors/ARBs, and low dose diuretics for\ntreatment of hypertension. Use in co mbination with beta-blockers is of benefit in patients with\nchronic stable angina.\nContraindications:\nCardiogenic shock, unstable angina, significant aortic stenosis. Worsening angina or increased\nrisk of myocardial infarction may be seen", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2435, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "762a0144-680d-473e-8f71-d5fc8125edaf": {"__data__": {"id_": "762a0144-680d-473e-8f71-d5fc8125edaf", "embedding": null, "metadata": {"page_label": "48", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f37f44cf-6a50-4f0f-9dfc-5c4d61ed6e7b", "node_type": "4", "metadata": {"page_label": "48", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "b2051f6e53e9cd9a1aae788e45154bc318d06e3affe3f3d7110152880f7dc346", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 48\nCautions:\nDrug interactions: Beta -blockers enhance hypotensive effect of amlodipine. Amlodipine\nincreases exposure to simvastatin (dose of simvastatin should not exceed 20 mg per day).\nAmlodipine also increases exposure to ciclosporin and tacrolimus.\nSide effects:\nGenerally well tolerated. Side effects are dose related and commoner in women. Pedal edema\nis the chief side effect, seen in around 10% of people on 10 mg daily, and may be decreased in\npatients receiving angiotensin converting enzyme inhibitors or angiote nsin receptor blockers.\nHeadache and flushing related to vasodilation may disappear after a few days.\nUse in Pregnancy and breast feeding\nPregnancy Class C. Use if potential benefits outweigh risk.  Avoid in lactation.\nHepatic impairment: may need dose reduction\nRenal impairment: No modification of drug dose is required.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 888, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fad131bc-10b3-4e2c-854e-b94c70e7dc1e": {"__data__": {"id_": "fad131bc-10b3-4e2c-854e-b94c70e7dc1e", "embedding": null, "metadata": {"page_label": "49", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1368e1c6-16ee-4795-a25b-a95225298012", "node_type": "4", "metadata": {"page_label": "49", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "709270c290d849923b2b4c47dda6fe7bda50bb5ce689a85a3390bc746e829a0b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 49\nAngiotensin converting enzyme inhibitors with focus on enalapril and its use in hypertension\nPharmacology: Angiotensin converting enzyme (ACE) inhibitors are drugs which inhibit the\nconversion of angiotensin I to angiotensin II (a potent vasoconstrictor) and the degradation of\nbradykinin. They represent a real advance in cardiovascular therapy and have broad s pectrum\nof proven beneficial effects in heart failure, hypertension, renal disease and cardio -protection\nafter myocardial infarction. They are generally well tolerated with no effect on blood glucose or\nlipids, with adverse effects which are occasional (e. g. cough), or quite rare (e.g. Angioedema).\nThese adverse effects are not dose related. Some adverse effects are seen when administered\nin patients with heart failure on high dose diuretics (first dose hypotension), or pre -existing\nrenal parenchymal and va scular disease (rise in creatinine, hyperkalaemia), which may be dose\nrelated. Use of all ACE inhibitors is contraindicated in pregnancy.\nIndications for enalapril:\nHypertension, heart failure (all stages), nephropathy (non -diabetic and diabetic), cardio -\nprotection in early phase acute MI and post-MI LV dysfunction.\nDose, titration, and use in combinations :Initial dose in hypertension: 5 mg in one or two\ndivided doses daily. In patients who have received diuretics, those who were elderly, the initial\ndoes may be 2.5 mg 5. The dose may be usually increased to 10 mg above which the additional\nbenefit may be minimal6, although the maximum dose mentioned for hypertension is 20 mg per\nday.\nEnalapril can be used in combination with low dose diuretics, calcium cha nnel blockers for\ntreatment of hypertension. ACE inhibitors should not be combined with ARBs.\nContraindications: Pregnancy is a contraindication for use of ACE inhibitors. B ilateral renal\nartery stenosis, History of hypersensitivity (including angioedema).\nCautions:\nRenal function may be assessed before starting therapy. In patients receiving diuretics\nespecially high dose diuretics, there is a risk of first dose hypotension, which may be minimised\nby usi ng a low dose of enalapril, close medical supervision. Up to 30% increase in serum\ncreatinine may occur on starting ACE inhibitors, which is reversible. Hyperkalemia can occur if\nthere is renal impairment, or patient is on potassium containing salt substitutes.\nSide effects:\n570. Opie L.H, Gersh B.J, editors. Drugs for the Heart. 8th ed: Saunders; 2013.\n670. Ibid.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2521, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "436a2a42-6c2c-4b49-ab08-3a7ff6e2aa79": {"__data__": {"id_": "436a2a42-6c2c-4b49-ab08-3a7ff6e2aa79", "embedding": null, "metadata": {"page_label": "50", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8e4ab208-ccaf-4c0d-924c-28ed7f9c6dd9", "node_type": "4", "metadata": {"page_label": "50", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "10fd48223f7c326c496e5b8825b892eeddf46317417eba75f27e3b6a1aff1bf8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 50\nGenerally well tolerated. Cough is the most common side effect; angioedema is rare and may\nbe potentially serious.\nBreast feeding: Limited information. Do not use enalapril for the first few weeks of life,\nespecially in the case of preterm infants because of risk of neonatal hypotension\nPregnancy Class D Use in second and third trimesters confers risk of oligohydramnios, and birth\nmalformations.\nHepatic impairment: may need dose reduction, and close monitoring.\nRenal impairment: may need dose reduction when creatinine clearance is less than <30 ml/min\n(approximate serum creatinine 3 mg/dl), when dose should be 2.5 mg once a day.7\n7 US FDA full prescribing information for enalapril.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 733, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c3431bb9-2202-4732-b32c-932453fb4b11": {"__data__": {"id_": "c3431bb9-2202-4732-b32c-932453fb4b11", "embedding": null, "metadata": {"page_label": "51", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "322ce154-6a70-4d4e-bc3e-2db338c6b258", "node_type": "4", "metadata": {"page_label": "51", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "1c181970c642c636a126adb9f49d9b36e9c64e6f6084fd0dd2a456a997ae7da1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 51\nThiazide diuretics for use in hypertension with special focus on low dose hydrochlorothiazide:\nThey act by increasing sodium excretion. Thiazide diuretics are useful agents in the therapy of\nhypertension as first line drugs and as add on therapy when initial therapy with calcium channel\nblockers, ACE inhibitors does not achieve target for BP c ontrol. Benefits on cardiovascular\noutcomes have been proven for hydrochlorothiazide, chlorthalidone and indapamide. They are\nlong acting agents effective as once a day therapy. In high doses(25 mg and above) thiazides\nhave metabolic side effects like glu cose intolerance, worsening of lipids, hypokalaemia, but\ngiven in low doses (12.5 mg) they exert near maximal lowering of BP without producing\nbiochemical changes as noted above. Thiazide like agents like chlorthalidone, indapamide are\nalso available, which are longer acting th an hydrochlorothiazide, and have beneficial outcomes\non cardiovascular mortality documented in clinical trials.\nIndications for thiazides:\nHypertension, Heart failure\nDose, titration, and use in combinations in hypertension\nDose in hypertension: 12. 5 mg once daily. Increasing the dose to 25 mg daily may not increase\nantihypertensive effect but can increase risk of hyperglycemia.\nLow dose hydrochlorothiazide can be used in combination with calcium channel blockers, and\nACE inhibitors for treatment of hypertension. The combination of thiazide diuretics with beta -\nblockers is not preferred as it increases the risk of new onset diabetes as well has an adverse\neffect on lipids.\nContraindications: severe hypokalemia, hyponatremia, hypercalcemia.\nCautions\nThiazides can worsen glycemiccontrol and gout.\nSide effects: Gastro-intestinal di sturbances, orthostatic hypotension, altered plasma lipid\nconcentration, metabolic and electrolyte disturbances (including hypokalaemia ,\nhyponatraemia, hypomagnesaemia, hypercalcaemia , hyperglycaemia). Occasional\nthrombocytopenia, impotence.\nPregnancy: Not used to treat hypertension in pregnancy. Administration in third trimester\ncarries risk of neonatal thrombocytopenia.\nHepatic impairment: Avoid in severe liver disease; hypokalemia may precipitate hepatic\nencephalopathy", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2245, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8ff0fcc8-84b0-4b10-98bf-7bff78ff6105": {"__data__": {"id_": "8ff0fcc8-84b0-4b10-98bf-7bff78ff6105", "embedding": null, "metadata": {"page_label": "52", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ffeedfa5-0485-4713-a8b8-be5352df805d", "node_type": "4", "metadata": {"page_label": "52", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "7fd93a2bc0cb6329be0dc74392c76d59bdd746264f93c47d78cdb601704b359b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quick Reference Guide-Hypertension Page 52\nRenal impairment: Avoid if creatinine clearance is less than <30 ml/min (approximate serum\ncreatinine 3 mg/dl), when they may be ineffective.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 184, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cced6c9b-7764-4c9b-8b4c-61ab9c6fd3ae": {"__data__": {"id_": "cced6c9b-7764-4c9b-8b4c-61ab9c6fd3ae", "embedding": null, "metadata": {"page_label": "53", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bee0412b-b3c4-47fd-b240-21b5feaeb4ac", "node_type": "4", "metadata": {"page_label": "53", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "15c19d82804b06ed6e9d4eb1b7ded7f18df75a11ec88bc4eeeadbacf80810870", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc8f00e9-e33d-40ab-97ce-562f3348f508", "node_type": "1", "metadata": {}, "hash": "a5164f2b3c574fb1551a95925aac46cc10028acf85b1de730a862616279adb74", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "HYPERTENSION\nScreening, diagnosis, assessment, and management\nof primary hypertension in adults in india\nStandard Treatment Guidelines - Ready Reckoner\nMay 2016\nMinistry of Health and Family Welfare\nGovernment of India\nOVERVIEW\nCardiovascular disease is the leading cause of death (including premature death) in India.\nHypertension is the leading risk factor for cardiovascular disease.\nIts prevalence is rising and approaches a third of all adults in urban India.\nIt is symptomatic only when the BP is extremely high or when complications occur.\nUncontrolled hypertension is a \u2018silent killer\u2019 . It can cause serious complications \nlike stroke (paralysis), heart attack, heart failure, kidney failure and vision loss.\nOnly a quarter of adults in India are aware of their BP status, only a quarter of \nhypertensives are on treatment, and only 10-20% of hypertensives have their \nBP under control.  \nPrevention, detection, and effective management of hypertension can prevent \ndeaths and serious disability in lakhs of people, and save hundreds of crores in \nhealthcare costs every year.\nThis standard treatment guideline has been developed for the management of \nhypertension in the Indian context and has a primary care focus and a \npublic health approach.\nFOLLOW UP , MONITORING AND IMPROVING ADHERENCE\nTeam approach involving physicians, allied staff and community based health workers.\nHypertension registry at PHC and CHC level to ensure tracking of patients.\nMonitor every 1-2 weeks till target BP achieved. Thereafter frequency determined by \nseverity of hypertension, co-morbidities, and target organ damage.\nAnnual review of control of BP , implementation of lifestyle modifications, target organ \ndamage, review of treatment including side effects of drugs.\nPeople with high normal BP should also be advised appropriate lifestyle modifications and \nencouraged to undergo an annual review.\nImprove adherence by\n\u2022\t a simplified regime using long acting drugs once a day\n\u2022\t streamlined methods of dispensing drugs and pill counts\n\u2022\t supervision by a family member\n\u2022\t periodic counselling and patient information leaflets\n\u2022\t home blood pressure monitoring using a validated automated device\nPREVENTION\nPromotion of a five point population-wide intervention\n\u2022\t Weight reduction in the obese\n\u2022\t Regular exercise in the sedentary\n\u2022\t Decrease salt, sugar and fat  intake\n\u2022\t Quit tobacco use\n\u2022\t Moderation of alcohol intake\nIncreased intake of fruits and vegetables in addition to decreased salt intake has the \npotential to lower blood pressure significantly.\nThis prescription for healthy living along with avoidance of tobacco use can also prevent \nobesity, diabetes, cardiovascular disease and many common types of cancer.\nDrug group Compelling \nindications\nCompelling \ncontraindications\nUsual dose\n(reduce in elderly)\nSide effects\nThiazide diuretics\nHydrochlorothiazide\nIsolated systolic \nhypertension \n(in elderly)\nGout 12.5-25 mg Metabolic \u2013 \nhypokalemia,\nhyperglycemia,\nhyperuricemia\nLow dose \nminimizes \nmetabolic effects\nACE inhibitors\nEnalapril\nDiabetes (especially\nwith proteinuria or \ncardiac disease)\nHistory of stroke, MI, \nhypertension with \nheart failure\nCKD where close \nbiochemical \nmonitoring possible\nPregnancy\nHyperkalemia\nBilateral renal \nartery stenosis\n5 -20 mg \n(enalapril)\nDry irritating \ncough\nAngioedema\nHyperkalemia \nand reversible \ndecline in renal \nfunction in some\nCalcium channel \nblockers\nAmlodipine\nIsolated systolic \nhypertension\n(in elderly)\nCKD where close \nbiochemical \nmonitoring NOT \nfeasible\nNo compelling \ncontraindication.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3567, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fc8f00e9-e33d-40ab-97ce-562f3348f508": {"__data__": {"id_": "fc8f00e9-e33d-40ab-97ce-562f3348f508", "embedding": null, "metadata": {"page_label": "53", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bee0412b-b3c4-47fd-b240-21b5feaeb4ac", "node_type": "4", "metadata": {"page_label": "53", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "15c19d82804b06ed6e9d4eb1b7ded7f18df75a11ec88bc4eeeadbacf80810870", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cced6c9b-7764-4c9b-8b4c-61ab9c6fd3ae", "node_type": "1", "metadata": {"page_label": "53", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "c1ab7fbc3c13b8231e60cb190626b429306adf1cef09a000534cc6c638abdf59", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Heart failure, \ntachyarrhythmia \nare possible \ncontraindications\n5-10 mg Pedal edema at \nhigher doses\nHeadache\nTachycardia\nBeta-blockers\nAtenolol\nPrevious MI\nHeart failure \n(use metoprolol, \nbisoprolol, \ncarvedilol)\nAsthma\nAV block\n25-100 mg \n(atenolol)\nFatigue, reduced \nexercise tolerance \nHyperglycemia \nespecially when \ncombined with \ndiuretics\nAngiotensin receptor \nblockers\nLosartan\nAs in ACE inhibitors\nUse if ACE inhibitors \nhave side effects like \ncough\nPregnancy\nHyperkalemia\nBilateral renal \nartery stenosis\n50-100 mg \n(losartan)\nCough (rare)\nHyperkalemia \nand reversible \ndecline in renal \nfunction in some\nAdjunctive therapy\nLow dose aspirin may be given to patients with hypertension and cardiovascular disease, or \nwell controlled hypertensives with high cardiovascular risk (>3 risk factors).\nStatins are indicated in hypertensives with cardiovascular disease, LDL-C >190 mg/dl, \ncoexisting diabetes, or multiple cardiovascular risk factors.\nThis guideline has been developed by the Medicine Sub-group of the Task Force for the Development \nof Standard Treatment Guidelines for the National Health Mission of the Ministry of Health and Family \nWelfare, Government of India.\nFURTHER READING\n1 STG for Screening, Diagnosis, Assessment, Management of Primary Hypertension in Adults in \nIndia \u2013 Quick Reference Guide. MoHFW, GOI 2016\nContains key recommendations, clinical pathways and a formulary for healthcare providers.\n2 STG for Screening, Diagnosis, Assessment, Management of Primary Hypertension in Adults in \nIndia \u2013 Full Guideline. MoHFW, GOI 2016\nContains details of recommendations with evidence base and methodology followed in developing \nthe guidelines and implementation issues for healthcare providers and programme managers.\nMonitor side effects of drugs\n\u2022\t Calcium channel blockers \u2013 peripheral edema. Dose-dependent, may subside \nwith reduction of dose or combination with ACE inhibitor.\n\u2022\t Diuretics \u2013 hypokalemia, hyperglycemia. Less frequent at lower doses and when \ncombined with ACE inhibitors. Thiazide induced hyponatremia commoner in \nelderly. Can develop rapidly \u2013 altered consciousness or seizures.\n\u2022\t ACE inhibitors \u2013 dry cough. May necessitate withdrawal. Risk of hypotension \nwith ACE inhibitors in patients already on diuretics, or on a very low salt diet. \nHyperkalemia can develop with high doses of ACE inhibitors, more commonly \nin those with renal insufficiency, diabetes, concurrent use of potassium sparing \ndiuretics, and the elderly. A small reversible rise in serum creatinine can occur. \nHYPERTENSIVE URGENCIES AND EMERGENCIES\nSBP>180, DBP>110-120\nAssess for following and investigate as appropriate: creatinine (all), x-ray chest, ECG, CT scan \nA Altered consciousness \nB Breathlessness \nC Chest pain (ischemic) \nD Deficit (weakness in one or more limbs) or decreased urinary output \nE Edema \nF Fundus if feasible- hemorrhages, exudates, papilledema \nG Generalized seizures\nHYPERTENSIVE URGENCY  - none of the above\nUse oral drugs\nReduce BP over hours to days \nHYPERTENSIVE EMERGENCY \u2013 one or more of the above\nReduce BP (only rarely to normal) over minutes to hours, according to type of emergency \nUse parenteral drugs, choice depends upon type of emergency (see list below) \nDO NOT USE SUBLINGUAL NIFEDIPINE \nTypes of hypertensive emergencies\nAccelerated Malignant Hypertension \nCardiac  \u2013 acute left ventricular failure, myocardial infarction, unstable angina \nNeurologic  \u2013 hypertensive encephalopathy, ischemic stroke, intracranial hemorrhage, head injury \nRenal \u2013 acute glomerulonephritis#, renovascular hypertension \nSurgical \u2013 post-operative hypertension, severe burns \nObstetric \u2013 eclampsia# \n# Hypertensive emergency may occur even at BP levels lower SBP 180 and DBP 110 mmHg", "mimetype": "text/plain", "start_char_idx": 3568, "end_char_idx": 7311, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cae44418-e154-4dc2-b68d-b1ec6635de20": {"__data__": {"id_": "cae44418-e154-4dc2-b68d-b1ec6635de20", "embedding": null, "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0153d763-c827-49a8-9d7f-4bf6ba531047", "node_type": "4", "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "e42e908bda4f4e4f23ae17a96c3866d51beef610466e37a9faee7956b99d2a18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e916b8f2-cec9-4ae9-941d-5f3453a9a86e", "node_type": "1", "metadata": {}, "hash": "7130072895bb9460aa03f2f86859d5def83662369ddbb8c6143c3f671f0d628c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "EVALUATION\nAssess the presence of \n\u2022\t other cardiovascular risk factors\n\u2022\t target organ damage (LVH or heart failure, proteinuria, renal failure, retinopathy)\n\u2022\t associated clinical conditions (diabetes, ischemic heart disease, cerebrovascular \ndisease, CKD) \nEssential evaluation \n\u2022\t History \u2013 cardiovascular risk factors (diet and exercise patterns, smoking, alcohol \nconsumption, family history of premature CAD) symptoms of target organ \ndamage or associated clinical conditions (breathlessness, angina, history of \ntransient ischemic attack or stroke)\n\u2022\t Examination \u2013 weight, height, BMI, unequal pulses, raised jugular venous \npulsations, S3 gallop, and pedal edema\n\u2022\t Investigation \u2013 fasting capillary/blood sugar, proteinuria\nDesirable evaluation in patients with Grade 2 hypertension, diabetes or proteinuria\n\u2022\t History, examination \u2013 as above\n\u2022\t Investigations \u2013 as above PLUS serum creatinine, fasting lipid profile, ECG\nComprehensive evaluation in patients with Grade 3 hypertension, CKD, heart failure \n\u2022\t History and examination \u2013 as above PLUS fundus examination PLUS examine \nfor clues for secondary hypertension (moon facies, unequal pulses, postural \nhypotension, renal artery bruit, palpable kidneys)\n\u2022\t Investigations \u2013 as above PLUS serum electrolytes, USG abdomen, 2-D Echo\nSCREENING \u2013 Zero Cost-No Pain-High Gain Procedure\nOpportunistic screening for hypertension should occur at every encounter with the \nhealth system including with community based health workers. \nTargeted screening for hypertension should be community based and target those at risk \nof developing hypertension \u2013 age over 50 years, overweight and obese persons, those \nwith diabetes, existing cardiovascular disease, those with family history of hypertension \nand smokers.\nMeasuring blood pressure\n1 Choice of BP device\nMercury sphygmomanometer or any other device (including electronic digital \noscillometric devices) validated using a standard protocol, and calibrated regularly.\n2 Patient preparation and position \nPatient should relax for 5 minutes before measurement. Should not have had \ncaffeine in the past hour or smoked in the past 30 minutes.  Should be seated \ncomfortably with back supported, arm at heart level, and legs uncrossed.\n3 Cuff size and placement\nAppropriate cuff size \u2013 length of bladder 80% of arm circumference, width 40% of \narm circumference. Use a large adult cuff for an obese patient. Patient should not \nwear any constrictive clothing. Place midline of cuff over pulsation of the brachial \nartery, 2-3 cm above the cubital fossa.\n4 Procedure\nFor auscultation based BP measurement, inflate cuff to 30 mm beyond the \ndisappearance of the radial pulse. Deflate cuff at 2-3 mm per second and record \nthe first and the last sounds by auscultation over the brachial artery as the systolic \nand diastolic blood pressure respectively.\nFor oscillometric devices follow the manufacturer\u2019s instructions and the BP will be \ndisplayed automatically.\n5 Number of measurements and recording the result\nAt least 2 readings at an interval of 2 minutes. If readings differ by more than \n5 mmHg take a third reading. The lower of the readings should be taken as the \nrepresentative SBP and DBP .\nRecommended action on BP readings (in mmHg) for persons screened by health workers  \nSBP \u2265180 and/or DBP \u2265110 with or without complications REFER IMMEDIATELY to PHC/CHC\nSBP 160-179 and/or DBP 100-109 refer to PHC within 1 week\nSBP 140-159 and/or DBP 90-99 refer to PHC within 1 month\nSBP 130-139 and/or DBP 85-89 recheck in 1 year\nSBP < 120 and DBP <80 recheck in 2 years\nDIAGNOSIS, CLASSIFICATION \nHypertension is systolic BP 140 mmHg or higher and diastolic BP 90 mmHg or higher.\nTWO readings on at least TWO occasions.\nValid device and standardised BP measurement procedure.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3784, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e916b8f2-cec9-4ae9-941d-5f3453a9a86e": {"__data__": {"id_": "e916b8f2-cec9-4ae9-941d-5f3453a9a86e", "embedding": null, "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0153d763-c827-49a8-9d7f-4bf6ba531047", "node_type": "4", "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "e42e908bda4f4e4f23ae17a96c3866d51beef610466e37a9faee7956b99d2a18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cae44418-e154-4dc2-b68d-b1ec6635de20", "node_type": "1", "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "7ceb639d4b782fa44da21a17eb80c1de33d357fbda4a5b1a1c29a271942c37be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce14c619-d648-48cf-a004-ddc615bf5d4d", "node_type": "1", "metadata": {}, "hash": "a186ae49a24f440d6074fa3b42d237cff6147e126becfbea0ba8cd53acc92740", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Recommended action on BP readings (in mmHg) for persons screened by health workers  \nSBP \u2265180 and/or DBP \u2265110 with or without complications REFER IMMEDIATELY to PHC/CHC\nSBP 160-179 and/or DBP 100-109 refer to PHC within 1 week\nSBP 140-159 and/or DBP 90-99 refer to PHC within 1 month\nSBP 130-139 and/or DBP 85-89 recheck in 1 year\nSBP < 120 and DBP <80 recheck in 2 years\nDIAGNOSIS, CLASSIFICATION \nHypertension is systolic BP 140 mmHg or higher and diastolic BP 90 mmHg or higher.\nTWO readings on at least TWO occasions.\nValid device and standardised BP measurement procedure.\nCategory Systolic BP mmHg                      Diastolic BP mmHg\nOptimal <120 and <80\nNormal 120 \u2013 129 and/or 80 \u2013 84\nHigh Normal 130 \u2013 139         and/or 85 \u2013 89\nGrade 1 Hypertension 140 \u2013 159 and/or 90 \u2013 99\nGrade 2 Hypertension 160 \u2013 179 and/or 100-109\nGrade 3 Hypertension \u2265180 and/or \u2265110  \nIsolated Systolic Hypertension \u2265 140 and < 90\nHypertensive urgency 1 \u2265180 and/or \u2265110\nHypertensive emergency 2 \u2265180 and/or \u2265110\n1 Severe asymptomatic hypertension with no evidence of acute target organ damage\n2 Severe hypertension associated with ongoing target organ damage \u2013 \ncardiovascular (e.g. left ventricular failure), cerebral (e.g. hypertensive \nencephalopathy or stroke), renal (acute renal failure), Grade III-IV retinopathy\nALL PATIENTS REQUIRE LIFE-LONG LIFESTYLE MODIFICATION\nDietary change \u2013 salt restricted (<5g/day), low-fat diet\nReduce weight \u2013 target BMI 18.5-22.9 kg/m2\nRegular exercise \u2013 moderate intensity, 30 minutes, 5 days a week\nSTOP SMOKING\nGRADE 1 HYPERTENSION (SBP 140-159, DBP 90-99) with\nDiabetes OR TOD (proteinuria, LVH, retinopathy) OR associated clinical conditions\nOR more than 3 risk factors \u2013 \nmale\nmen aged >55 years, women aged >65 years\nsmoking\nobesity, including abdominal obesity\ndyslipidemia\nimpaired glucose tolerance\nfamily history of early coronary artery disease\nOR inadequate control after 3 months of lifestyle modification\nDrug therapy \u2013 A or C1 or D\nAdd second drug - A+C or C+D or A+D if response not adequate within 2-4 weeks\nAdd third drug \u2013 A+C+D if response not adequate within 2-4 weeks\nGRADE 2 HYPERTENSION (SBP 160-179, DBP 100-109)\nDrug therapy \u2013 A or C or D\nAdd second drug - A+C or C+D or A+D if response not adequate within 2-4 weeks\nAdd third drug \u2013 A+C+D if response not adequate within 2-4 weeks\nGRADE 3 HYPERTENSION (SBP \u2265180, DBP \u2265110)\nUse two drugs - A+C or C+D or A+D \nAdd third drug \u2013 A+C+D if response not adequate within 2-4 weeks\nALL GRADES OF HYPERTENSION WITH ASSOCIATED CLINICAL CONDITIONS\nCAD: coronary artery disease - B+A\n2, C\n CHF: congestive heart failure - D+A+B, MRA\n CKD: chronic kidney disease - A, C, D3\n DM: diabetes mellitus - A/C, D\nMANAGEMENT - target BP <140/90 mmHg,  <150/90 in patients over 80.\nThe overall aim is to reduce BP to target levels within 6-8 weeks and to reduce \ncardiovascular risk.\nPATIENT EDUCATION  discuss the following points\nNature of disease \u2013 hypertension is asymptomatic but can produce damage to heart, \nbrain, and kidney if uncontrolled.\nLifestyle measures \u2013 can reduce BP , reduce the doses of medicines, and reduce risk of \ndamage to the heart.\nTherapy \u2013 medicines should be taken every day without a break. The patient should \ninform the doctor if he notices any side effects.\nBP targets and monitoring \u2013 inform patients about target BP- which is generally < 140 \nmm systolic and <90 mm diastolic. Encourage patient to monitor BP at home, if possible.", "mimetype": "text/plain", "start_char_idx": 3207, "end_char_idx": 6655, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ce14c619-d648-48cf-a004-ddc615bf5d4d": {"__data__": {"id_": "ce14c619-d648-48cf-a004-ddc615bf5d4d", "embedding": null, "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0153d763-c827-49a8-9d7f-4bf6ba531047", "node_type": "4", "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "e42e908bda4f4e4f23ae17a96c3866d51beef610466e37a9faee7956b99d2a18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e916b8f2-cec9-4ae9-941d-5f3453a9a86e", "node_type": "1", "metadata": {"page_label": "54", "file_name": "6591.pdf", "file_path": "temp_uploads\\6591.pdf", "file_type": "application/pdf", "file_size": 1748005, "creation_date": "2025-12-11", "last_modified_date": "2025-12-11"}, "hash": "7a40a03a0a1993e1fb5a34bc55028b55ea9b306e6a8e983fb23e0e2eac90ac3b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The overall aim is to reduce BP to target levels within 6-8 weeks and to reduce \ncardiovascular risk.\nPATIENT EDUCATION  discuss the following points\nNature of disease \u2013 hypertension is asymptomatic but can produce damage to heart, \nbrain, and kidney if uncontrolled.\nLifestyle measures \u2013 can reduce BP , reduce the doses of medicines, and reduce risk of \ndamage to the heart.\nTherapy \u2013 medicines should be taken every day without a break. The patient should \ninform the doctor if he notices any side effects.\nBP targets and monitoring \u2013 inform patients about target BP- which is generally < 140 \nmm systolic and <90 mm diastolic. Encourage patient to monitor BP at home, if possible.\nAbbreviations: CAD: coronary artery disease, CHF: congestive heart failure, CKD: chronic kidney disease, DBP: diastolic blood pressure, \nDM: diabetes mellitus, LVH: left ventricular hypertrophy, SBP: systolic blood pressure, TOD: target organ damage. \nDrug classes: A: Angiotensin converting enzyme (ACE) inhibitors, (e.g. enalapril) or Angiotensin II receptor blockers (ARBs, e.g. losartan) \nonly if intolerance to ACE inhibitors, B: beta-blockers (e.g. atenolol), C: calcium channel blockers (e.g. amlodipine), D: thiazide diuretics \n(e.g. hydrochlorothiazide), MRA: mineralocorticoid receptor antagonist (e.g. spironolactone).\nFootnotes:\n1  Calcium channel blockers are antihypertensives of choice in the elderly (> 60 years).\n2  Patients with CAD and history of myocardial infarction should receive both beta-blockers and ACE inhibitors.\n3  Patients with CKD may need loop diuretics if GFR is low. Those on ACE inhibitors need regular monitoring of creatinine and potassium.", "mimetype": "text/plain", "start_char_idx": 5971, "end_char_idx": 7634, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}}